UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~FORM 10-Q

~~(Mark One)~~

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

~~For the quarterly period ended~~ ~~September 30, 2021~~

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

Commission file number: ~~000-53316~~001-41396

SOBR ~~Safe, Inc.~~SAFE, INC.

(Exact name of registrant as specified in its charter)

Delaware		26-0731818
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

~~885 Arapahoe Avenue~~6400 S. Fiddlers Green Circle, Suite 525 ~~Boulder, CO~~Greenwood Village, Colorado		~~80302~~80111
(Address of principal executive offices)		(Zip Code)

~~(844) 762-7723~~

Registrant’s telephone number, including area code

~~________________________________________~~

~~(Former name, address, if changed since last report)~~

~~(Former fiscal year, if changed since last report)~~(844) 762-7723

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
~~None~~ Common Stock		~~None~~ SOBR		~~None~~The Nasdaq Stock Market LLC (Nasdaq Capital Market)

~~Securities registered pursuant to Section 12(g) of the Act:~~

~~Common Stock, $0.00001 par value~~

~~(Title of class)~~

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated ~~filer~~Filer	☒☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.☒

Applicable only to issuers involved in bankruptcy proceedings during the preceding five years:

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

Applicable only to corporate issuers:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of ~~November 12, 2021,~~May 20, 2022, there were ~~25,981,203~~10,156,081 shares of common stock, $0.00001 par value, issued and outstanding.

SOBR SAFE, INC.

TABLE OF CONTENTS

Table of Contents

PART I – FINANCIAL INFORMATION

Forward-Looking Statement Disclaimer

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider,” or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties, and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

Reverse Stock Split on April 28, 2022

At the open of market on ~~June 8, 2020,~~April 28, 2022, our ~~1-for-33.26~~1-for-3 reverse split of our common stock went effective with ~~OTC Markets.~~FINRA and our trading market. As a result, all common stock share amounts, as well as share amounts and exercise and conversion prices in derivative security instruments have been adjusted to reflect the reverse stock split.

Table of Contents

ITEM 1 Condensed Consolidated Financial Statements

The condensed consolidated balance sheets as of ~~September 30, 2021~~March 31, 2022, and December 31, ~~2020,~~2021, the condensed consolidated statements of operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, and 2021, ~~and 2020,~~ the condensed consolidated statements of changes in stockholders’ ~~equity (deficit)~~deficit for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, and 2021, ~~and 2020,~~ and the condensed consolidated statements of cash flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2022, and 2021, ~~and 2020,~~ follow. The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.

~~SOBR Safe, Inc.~~

~~CONDENSED CONSOLIDATED BALANCE SHEETS~~

September 30,
2021

December 31,
2020

(Unaudited)

(Audited)

ASSETS

Current assets

Cash

$ 2,185,233

$ 232,842

Prepaid expenses

24,899

115,230

Total current assets

2,210,132

348,072

SOBR Safe Intellectual Technology, net of accumulated amortization of $513,952 and $224,854 at September 30, 2021 and December 31, 2020, respectively

3,340,723

3,629,821

Other assets

15,826

8,680

Total Assets

$ 5,566,681

$ 3,986,573

LIABILITIES & STOCKHOLDERS' EQUITY

Current liabilities

Accounts payable

$ 706,142

$ 101,308

Accrued expenses

306,071

313,032

Accrued interest payable

193,177

134,444

Related party payables

29,404

28,624

Common stock subscriptions payable

228,046

253,688

Derivative liability

980,000

0

Convertible debenture payable

* Includes unamortized debt discount related to detached warrants and convertible debenture of $2,608,900 and none at September 30, 2021 and December 31, 2020, respectively

439,881 *

0

Current portion notes payable - related parties

11,810

11,810

Current portion notes payable - non-related parties

104,183

79,183

Total current liabilities

2,998,714

922,089

Notes payable -related parties-less current portion

* Includes unamortized debt discount and beneficial conversion feature related to detached warrants and convertible notes of $771,576 and none at September 30, 2021 and December 31, 2020, respectively

228,424 *

0

Notes payable -non-related parties-less current portion

* Includes unamortized debt discount and beneficial conversion feature related to detached warrants and convertible notes of $774,850 and none at September 30, 2021 and December 31, 2020, respectively

230,150 *

25,000

Total Liabilities

3,457,288

947,089

Stockholders' Equity

Preferred stock, $0.00001 par value; 19,300,000 shares authorized, no shares issued or outstanding as of September 30, 2021 and December 31, 2020

0

0

Series A Convertible Preferred stock, $0.00001 par value; 3,000,000 shares authorized, no shares issued or outstanding as of September 30, 2021 and December 31, 2020

0

0

Series A-1 Convertible Preferred stock, $0.00001 par value; 2,700,000 shares authorized, no shares issued or outstanding as of September 30, 2021 and December 31, 2020

0

0

Common stock, $0.00001 par value; 100,000,000 shares authorized; 25,981,203 and 25,922,034 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively

260

260

Additional paid-in capital

56,330,450

52,693,974

Accumulated deficit

(54,167,685 )

(49,601,220 )
Total SOBR Safe, Inc. stockholders' equity

2,163,025

3,093,014

Noncontrolling interest

(53,632 )

(53,530 )

Total Stockholders' Equity

2,109,393

3,039,484

Total Liabilities and Stockholders' Equity

$ 5,566,681

$ 3,986,573

The accompanying notes are an integral part of the condensed consolidated financial statements.
4
Table of Contents

SOBR SAFE, Inc.
CONDENSED CONSOLIDATED ~~STATEMENTS OF OPERATIONS~~BALANCE SHEETS
~~(UNAUDITED)~~

For The Three Months Ended

For The Nine Months Ended

September 30,

September 30,

September 30,

September 30,

2021

2020

2021

2020

Revenues

$ 0

$ 0

$ 0

$ 0

Operating expenses:

General and administrative

316,329

191,589

875,378

400,127

Stock-based compensation expense

147,163

0

334,228

41,302

Management salaries and consulting fees

632,964

352,266

1,682,557

1,103,828

Research and development

566,655

152,123

1,052,650

309,403

Asset impairment adjustment

0

0

0

25,320,555

Total operating expenses

1,663,111

695,978

3,944,813

27,175,215

Loss from operations

(1,663,111 )

(695,978 )

(3,944,813 )

(27,175,215 )

Other income (expense):

Loss on extinguishment of debt, net

0

0

-

(269,144 )
Gain on fair value adjustment - derivatives

0

0

0

60,650

Interest expense

(227,475 )

(41,622 )

(399,381 )

(107,253 )
Amortization of interest - conversion features

(130,830 )

0

(222,373 )

(1,407,675 )
Total other expense, net

(358,305 )

(41,622 )

(621,754 )

(1,723,422 )

Loss before provision for income taxes

(2,021,416 )

(737,600 )

(4,566,567 )

(28,898,637 )

Provision for income taxes

0

0

0

0

Net loss

(2,021,416 )

(737,600 )

(4,566,567 )

(28,898,637 )
Net (income) loss attributable to noncontrolling interest

4

(98 )

102

(48 )

Net loss attributable to SOBR Safe, Inc.

(2,021,412 )

(737,698 )

(4,566,465 )

(28,898,685 )
Accrued dividends on convertible preferred stock

0

(161,880 )

0

(161,880 )
Net loss attributable to common stockholders

$ (2,021,412 )

$ (899,578 )

$ (4,566,465 )

$ (29,060,565 )

Basic and diluted loss per common share

$ (0.08 )

$ (0.04 )

$ (0.18 )

$ (2.23 )

Weighted average number of common shares outstanding

25,981,203

20,046,424

25,974,042

13,030,845

March 31,

December 31,

2022

2021

ASSETS

(Unaudited)

(Audited)

Current assets

Cash

$ 107,448

$ 882,268

Accounts receivable

500

0

Inventory

104,950

39,461

Prepaid expenses

29,286

12,553

Total current assets

242,184

934,282

SOBR Safe Intellectual Technology, net of accumulated amortization of $706,684 and $610,318 at March 31, 2022 and December 31, 2021, respectively

3,147,991

3,244,357

Other assets

30,576

30,576

Total Assets

$ 3,420,751

$ 4,209,215

LIABILITIES & STOCKHOLDERS' DEFICIT

Current liabilities

Accounts payable

$ 367,036

$ 270,150

Accrued expenses

1,395,696

463,900

Accrued interest payable

309,809

252,110

Related party payables

95,320

82,883

Derivative liability

1,380,000

1,040,000

Convertible debenture payable

* Includes unamortized debt discount related to warrants, beneficial conversion feature and embedded conversion feature of none and $1,291,882 at March 31, 2022 and December 31, 2021, respectively

3,048,781 *

1,756,899 *
Current portion notes payable - related parties

* Includes unamortized debt discount related to warrants and beneficial conversion features of $259,658 and none at March 31, 2022 and December 31, 2021, respectively

302,152 *

11,810 *
Current portion notes payable - non-related parties

* Includes unamortized debt discount related to warrants and beneficial conversion features of $258,175 and none at March 31, 2022 and December 31, 2021, respectively

348,508 *

104,183 *
Total current liabilities

7,247,302

3,981,935

Notes payable -related parties-less current portion

* Includes unamortized debt discount related to warrants and beneficial conversion features of $262,604 and $645,547 at March 31, 2022 and December 31, 2021, respectively

187,396 *

354,453 *
Notes payable -non-related parties-less current portion

* Includes unamortized debt discount related to warrants and beneficial conversion features of $261,396 and $648,580 at March 31, 2022 and December 31, 2021, respectively

193,604 *

356,420 *

Total Liabilities

7,628,302

4,692,808

Stockholders' Deficit

Non Series Preferred stock, $0.00001 par value; 16,300,000 and 19,300,000 shares authorized at March 31, 2022 and December 31, 2021, respectively, no shares issued or outstanding at March 31, 2022 and December 31, 2021

0

0

Series A Convertible Preferred stock, $0.00001 par value; 3,000,000 shares authorized, no shares issued or outstanding at March 31, 2022 and December 31, 2021

0

0

Series A-1 Convertible Preferred stock, $0.00001 par value; 2,700,000 shares authorized, no shares issued or outstanding as of March 31, 2022 and December 31, 2021

0

0

Series B Convertible Preferred stock, $0.000001 par value: 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at March 31, 2022 and none at December 31, 2021, respectively

30

0

Common stock, $0.00001 par value; 100,000,000 shares authorized; 7,803,139 and 8,778,555 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

78

88

Additional paid-in capital

58,887,152

57,041,447

Accumulated deficit

(63,041,171 )

(57,471,492 )
Total SOBR Safe, Inc. stockholders' deficit

(4,153,911 )

(429,957 )
Noncontrolling interest

(53,640 )

(53,636 )

Total Stockholders' Deficit

(4,207,551 )

(483,593 )

Total Liabilities and Stockholders' Deficit

$ 3,420,751

$ 4,209,215

The accompanying notes are an integral part of the condensed consolidated financial statements.

~~The accompanying notes are an integral part of the condensed consolidated financial statements.~~
5
Table of Contents

SOBR SAFE, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF ~~CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)~~OPERATIONS
~~(UNAUDITED)~~


Common Stock

Preferred Stock

Stockholders'
Equity

Total

Amount

Amount

Additional

(Deficit)

Stockholders'

Shares

($0.00001 Par)

Shares

($0.00001 Par)

Paid-in
Capital

Accumulated
Deficit

SOBR Safe, Inc.

Noncontrolling
Interest

Equity (Deficit)

Balances at January 1, 2020

6,452,993

$ 65

-

$ 0

$ 15,971,392

$ (19,511,168 )

$ (3,539,711 )

$ (53,410 )

$ (3,593,121 )
Common stock issued for compensation

601

0

-

0

20,800

0

20,800

0

20,800

Common stock issued due to stock warrants exercise

454,097

4

-

0

65,724

0

65,728

0

65,728

Common stock issued to settle related party payables

214,883

2

-

0

493,072

0

493,074

0

493,074

Common stock issued to settle accounts payable and accrued expenses

38,323

0

-

0

92,385

0

92,385

0

92,385

Common stock issued to settle related party debt

648,739

6

-

0

826,958

0

826,964

0

826,964

Common stock issued to settle non-related party debt

70,448

1

-

0

166,525

0

166,526

0

166,526

Paid-in capital - fair value of stock options vested

-

0

-

0

39,450

0

39,450

0

39,450

Paid-in capital - gain on related party debt conversion

-

0

-

0

124,291

0

124,291

0

124,291

Paid-in capital - gain on related party payables conversion

-

0

-

0

221,557

0

221,557

0

221,557

Paid-in capital - loss on debt extinguishment

-

0

-

0

116,893

0

116,893

0

116,893

Paid-in capital - beneficial conversion feature

-

0

-

0

174

0

174

0

174

Net loss for the period

-

0

-

0

0

(450,023 )

(450,023 )

149

(449,874 )
Balances at March 31, 2020

7,880,084

$ 78

-

$ 0

$ 18,139,221

$ (19,961,191 )

$ (1,821,892 )

$ (53,261 )

$ (1,875,153 )

Common stock issued to settle accounts payable and accrued expenses

121,072

2

-

0

173,290

0

173,292

0

173,292

Common stock issued to settle related party payables

45,268

1

-

0

86,739

0

86,740

0

86,740

Common stock issued for asset purchase

12,000,000

120

-

0

27,119,880

0

27,120,000

0

27,120,000

Paid-in capital - beneficial conversion feature

-

0

-

0

1,407,501

0

1,407,501

0

1,407,501

Paid-in capital - fair value of stock warrants granted

-

0

-

0

695,454

0

695,454

0

695,454

Paid-in capital - gain on related party payables conversion

-

0

-

0

50,741

0

50,741

0

50,741

Paid-in capital - loss on extinguishment of convertible notes

-

0

-

0

273,462

0

273,462

0

273,462

Paid-in capital - fair value of stock options vested

-

0

-

0

257,482

0

257,482

0

257,482

Net loss for the period

-

0

-

0

0

(27,710,964 )

(27,710,964 )

(199 )

(27,711,163 )
Balances at June 30, 2020

20,046,424

$ 201

-

$ 0

$ 48,203,770

$ (47,672,155 )

$ 531,816

$ (53,460 )

$ 478,356

Paid-in capital - fair value of stock options vested

-

0

-

0

46,617

0

46,617

0

46,617

Dividends payable-Series A-1 convertible preferred stock

-

0

-

0

0

(161,880 )

(161,880 )

0

(161,880 )
Net loss for the period

-

0

-

0

0

(737,698 )

(737,698 )

98

(737,600 )
Balances at September 30, 2020

20,046,424

$ 201

-

$ 0

$ 48,250,387

$ (48,571,733 )

$ (321,145 )

$ (53,362 )

$ (374,507 )

Balances at January 1, 2021

25,922,034

$ 260

-

$ 0

$ 52,693,974

$ (49,601,220 )

$ 3,093,014

$ (53,530 )

$ 3,039,484

Common stock issued to settle dividends - Series A-1 Convertible Preferred stock

43,169

0

-

0

107,880

0

107,880

0

107,880

Paid-in capital - fair value of stock options and RSU vested

-

0

-

0

105,013

0

105,013

0

105,013

Paid-in capital - relative fair value of stock warrants granted

-

0

-

0

619,381

0

619,381

0

619,381

Paid-in capital - beneficial conversion feature

-

0

-

0

480,619

0

480,619

0

480,619

Net loss for the period

-

0

-

0

0

(1,002,340 )

(1,002,340 )

(94 )

(1,002,434 )
Balances at March 31, 2021

25,965,203

$ 260

-

$ 0

54,006,867

$ (50,603,560 )

$ 3,403,567

$ (53,624 )

$ 3,349,943

Common stock issued for facility lease

16,000

0

-

0

49,600

0

49,600

0

49,600

Paid-in capital - fair value of stock options and RSU vested

-

0

-

0

138,010

0

138,010

0

138,010

Paid-in capital - relative fair value of stock warrants granted

-

0

-

0

473,327

0

473,327

0

473,327

Paid-in capital - beneficial conversion feature

-

0

-

0

428,595

0

428,595

0

428,595

Net loss for the period

-

0

-

0

0

(1,542,713 )

(1,542,713 )

(4 )

(1,542,717 )
Balances at June 30, 2021

25,981,203

$ 260

-

$ 0

55,096,399

$ (52,146,273 )

$ 2,950,386

$ (53,628 )

$ 2,896,758

Paid-in capital - fair value of stock options and RSU vested

-

0

-

0

387,003

0

387,003

0

387,003

Paid-in capital - relative fair value of stock warrants granted

-

0

-

0

847,048

0

847,048

0

847,048

Net loss for the period

-

0

-

0

0

(2,021,412 )

(2,021,412 )

$ (4 )

(2,021,416 )
Balances at September 30, 2021

25,981,203

$ 260

-

$ 0

56,330,450

$ (54,167,685 )

$ 2,163,025

$ (53,632 )

$ 2,109,393

For The Three Months Ended
March 31,

2022

2021

(Unaudited)

(Unaudited)

Revenues

$ 1,500

$ 0

Cost of Goods Sold

1,100

0

Gross Profit

400

0

Operating expenses:

General and administrative

2,269,175

776,861

Stock-based compensation expense

442,784

18,690

Research and development

47,459

171,463

Total operating expenses

2,759,418

967,014

Loss from operations

(2,759,018 )

(967,014 )

Other income (expense):

Other income (expense), net

27

0

Loss on debt extinguishment

(864,000 )

0

Loss on fair value adjustment - derivatives

(340,000 )

0

Interest expense

(1,026,471 )

(25,878 )
Amortization of interest - beneficial conversion feature

(580,221 )

(9,542 )
Total other expense, net

(2,810,665 )

(35,420 )

Loss before provision for income taxes

(5,569,683 )

(1,002,434 )

Provision for income tax

0

0

Net loss

(5,569,683 )

(1,002,434 )
Net loss attributable to noncontrolling interest

4

94

Net loss attributable to SOBR Safe, Inc.

$ (5,569,679 )

$ (1,002,340 )

Basic and diluted loss per common share

$ (0.65 )

$ (0.12 )

Weighted average number of common shares outstanding

8,550,490

8,654,108

The accompanying notes are an integral part of the condensed consolidated financial statements.

6
Table of Contents

SOBR SAFE, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

For The Nine Months Ended

September 30,

2021

2020

Operating Activities:

Net loss

$ (4,566,567 )

$ (28,898,637 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

289,098

133,571

Loss on debt extinguishment, net

0

269,144

Change in fair value of derivative liability

0

(60,650 )
Amortization of interest - conversion features

222,373

1,407,675

Amortization of interest

275,052

8,656

Stock options expense

399,259

343,549

Stock-based compensation expense

334,228

41,302

Asset impairment adjustment

0

25,320,555

Changes in assets and liabilities:

Prepaid expenses

(19,361 )

994

Other assets

(7,146 )

(8,680 )
Accounts payable

604,834

140,906

Accrued expenses

(6,961 )

(83,495 )
Accrued interest payable

58,733

(6,697 )
Related party payables

780

(51,976 )
Common stock subscriptions payable

138,069

0

Net cash used in operating activities

(2,277,609 )

(1,443,783 )

Financing Activities:

Proceeds from notes payable - related parties

1,030,000

0

Repayments of notes payable - related parties

(30,000 )

0

Proceeds from notes payable - non-related parties

1,005,000

41,665

Proceeds from convertible debenture payable

2,500,000

0

Debt issuance costs

(275,000 )

0

Proceeds from offering of preferred stock - related parties

0

1,700,000

Net cash provided by financing activities

4,230,000

1,741,665

Net Change In Cash

1,952,391

297,882

Cash At The Beginning Of The Period

232,842

681,759

Cash At The End Of The Period

$ 2,185,233

$ 979,641

Schedule Of Non-Cash Investing And Financing Activities:

Issuance of common shares for rent

$ 49,600

$ 0

Issuance of common stock for prior year accrued dividends

$ 107,880

$ 0

Intrinsic value-beneficial conversion feature

$ 909,214

$ 1,407,501

Relative fair value of stock warrants granted

$ 1,939,756

$ 0

Convertible debenture payable discount

$ 823,781

$ 0

Fair value of embedded conversion feature

$ 980,000

$ 0

Gain on related party payables converted to capital

$ 0

$ 272,299

Accounts payable and accrued expenses converted to capital

$ 0

$ 265,677

Related party payables converted to capital

$ 0

$ 579,814

Related party debt converted to capital after exercise of cashless stock warrants

$ 0

$ 65,728

Related party debt converted to capital

$ 0

$ 826,964

Non-related party debt converted to capital

$ 0

$ 166,526

Gain on related party debt converted to capital

$ 0

$ 124,291

Shares issued for cash received in prior years

$ 0

$ 20,800

Issuance of common stock, stock warrants and convertible note for asset purchase

$ 0

$ 29,222,955

Preferred stock dividend accrued

$ 0

$ 161,880

Supplemental Disclosure:

Cash paid for interest

$ 67,618

$ 765

Cash paid for income taxes

$ 0

$ 0

The accompanying notes are an integral part of the condensed consolidated financial statements.
SOBR SAFE, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT(UNAUDITED)

Common Stock

Preferred Stock

Stockholders'

Amount

Amount

Additional

Deficit

Total

($0.00001

($0.00001

Paid-in

Accumulated

SOBR Safe,

Noncontrolling

Stockholders’

Shares

Par)

Shares

Par)

Capital

Deficit

Inc.

Interest

Deficit

Balances at January 1, 2021

8,640,678

$ 86

-

$ 0

$ 52,694,148

$ (49,601,220 )

$ 3,093,014

$ (53,630 )

$ 3,039,484

Common stock issued to settle dividends - Series A-1 Convertible Preferred stock

14,390

-

-

0

107,880

0

107,880

0

107,880

Paid-in capital - fair value of stock options and restricted stock units vested

-

0

-

0

105,013

0

105,013

0

105,013

Paid-in capital - fair value of stock warrants granted

-

0

-

0

619,381

0

619,381

0

619,381

Paid-in capital - beneficial conversion feature

-

0

-

0

480,619

0

480,619

0

480,619

Net loss

-

0

-

0

0

(1,002,340 )

(1,002,340 )

(94 )

(1,002,434 )
Balances at March 31, 2021

8,655,068

86

-

0

54,007,041

50,603,560

3,403,567

(53,624 )

3,349,943

Balances at January 1, 2022

8,778,555

$ 88

-

$ 0

$ 57,041,447

$ (57,471,492 )

$ (429,957 )

$ (53,636 )

$ (483,593 )
Common stock issued for restricted stock units

16,667

0

-

0

0

0

0

0

0

Common stock issued for convertible debt

7,917

0

-

0

47,500

0

47,500

0

47,500

Common stock exchanged for convertible preferred stock

(1,000,000 )

(10 )

3,000,000

30

(20 )

0

0

0

0

Paid-in capital - fair value of stock options and restricted stock units vested

-

0

-

0

934,225

0

934,225

0

934,225

Paid-in capital - fair value of stock warrants granted

-

0

-

0

864,000

0

864,000

0

864,000

Net loss

-

0

-

0

(5,569,679 )

(5,569,679 )

(4 )

(5,569,683 )
Balances at March 31, 2022

7,803,139

$ 78

3,000,000

$ 30

$ 58,887,152

$ (63,041,171 )

$ (4,153,911 )

$ (53,640 )

$ (4,207,551 )
The accompanying notes are an integral part of the condensed consolidated financial statements.

7
Table of Contents
SOBR SAFE, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For The Three Months Ended

March 31,

2022

2021

(Unaudited)

(Unaudited)

Operating Activities:

Net loss

$ (5,569,683 )

$ (1,002,434 )

Adjustments to reconcile net loss to net cash used in operating activities:

Amortization

96,366

96,366

Amortization of interest - conversion features

580,221

9,542

Amortization of interest

423,782

0

Loss on extinguishment of debt

864,000

0

Change in fair value of derivative liability

340,000

0

Stock warrants expense

540,176

13,472

Stock options expense

491,441

105,013

Stock-based compensation expense

442,784

18,690

Changes in assets and liabilities:

Accounts receivable

(500 )

0

Due from related parties

0

(2,792 )
Inventory

(65,489 )

0

Prepaid expenses

(16,733
)

5,559

Accounts payable

96,886

65,317

Accrued expenses

931,796

(30,566 )
Accrued interest payable

57,696

(42,950 )
Related party payables

12,437

7,533

Stock subscriptions payable

0

88,469

Net cash used in operating activities

(774,820 )

(668,781 )

Financing Activities:

Proceeds from notes payable - related parties

0

530,000

Proceeds from notes payable - non-related parties

0

600,000

Net cash provided by financing activities

0

1,130,000

Net Change In Cash

(774,820 )

461,219

Cash At The Beginning Of The Period

882,268

232,842

Cash At The End Of The Period

$ 107,448

$ 694,061

Schedule Of Non-Cash Investing And Financing Activities:

Non-related party debt converted to capital

$ 47,500

$ 0

Issuance of common stock for rent

$ 0

$ 49,600

Issuance of common stock for prior year accrued dividends

$ 0

$ 107,880

Issuance of common stock to settle prior year stock subscriptions payable

$ 0

$ 909,214

Intrinsic value-beneficial conversion feature

$ 0

$ 1,939,756

Conversion of common stock to preferred stock

$ 30

$ 0

Relative fair value of stock warrants granted

$ 0

$ 823,781

Convertible debenture payable discount

$ 0

$ 980,000

Supplemental Disclosure:

Cash paid for interest

$ 4,816

$ 57,378

Cash paid for income taxes

$ 0

$ 0

The accompanying notes are an integral part of the condensed consolidated financial statements.
8
Table of Contents

SOBR SAFE, Inc.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~September 30, 2021~~March 31, 2022

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SOBR Safe, Inc. (“SOBR Safe”), formerly TransBiotec, Inc., was incorporated as Imagine Media LTD. in August 2007 in the State of Delaware. A corporation also named TransBiotec, Inc. (“TransBiotec – CA”) was formed in the state of California July 4, 2004. Effective September 19, 2011, TransBiotec was acquired by TransBiotec - CA in a transaction classified as a reverse acquisition as the shareholders of TransBiotec - CA retained the majority of the outstanding common stock of TransBiotec after the share exchange. The consolidated financial statements represent the activity of TransBiotec - CA from July 4, 2004 forward, and the consolidated activity of SOBR Safe and TransBiotec - CA from September 19, 2011 forward. SOBR Safe and TransBiotec - CA are hereinafter referred to collectively as the “Company” or “We”. The Company has developed and ~~plans to market and sell~~began selling a non-invasive alcohol sensing ~~system which includes an ignition interlock. The Company has not generated any revenues from its operations.~~device in 2022.

On January 7, 2022, our stockholders approved an amendment to our Articles of Incorporation to effect a reverse stock split of our outstanding common stock at a ratio between of 1-for-2 and 1-for-3 in connection with our planned listing on Nasdaq. On March ~~23, 2020, the Company filed a Definitive 14C providing notice that~~4, 2022 the Board of Directors ~~has recommended, and that holders~~approved the reverse split ratio of ~~a majority~~1-for-3 with the anticipated effective date of the ~~voting power of the Company’s outstanding stock voted, to approve the following.~~
1.
~~To remove and re-elect four (4) directors to serve until the next Annual Meeting of Shareholders and thereafter until their successors are elected and qualified; and~~
2.
To approve an amendment to the Company’s Certificate of Incorporation to: (a) change the Company’s name to SOBR SAFE, Inc., (b) decrease the Company’s authorized common stock from 800,000,000 shares, par value $0.00001 to 100,000,000 shares, par value $0.00001, and (c) effect a reverse ~~stock~~ split of the Company’s outstanding common stock at a ratio between 1-for-32 and 1-for-35 (with the exact ratio to be determined by the directors in their sole discretion without further approval by the shareholders).
~~The above actions taken by the Company’s stockholders became effective~~ on or about ~~May 21, 2020.~~March 28, 2022. The ~~effective dates of the above actions were June 5, 2020 and April 20, 2020, respectively, and the actual~~1-for-3 reverse stock split ~~ratio was 1-for-33.26.~~went effective with the State of Delaware, FINRA and OTC Markets on April 28, 2022. All share and per share amounts have been adjusted in these condensed consolidated financial statements to reflect the effect of the reverse stock split.
Also on January 7, 2022, our stockholders also approved an amendment to our 2019 Equity Incentive Plan to increase the shares authorized to be issued under the Plan from 1,282,823 shares to 1,733,333 shares.

Basis of Presentation
The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and the notes thereto should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the year ended December 31, ~~2020,~~2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March ~~31, 2021.~~11, 2022.

In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, and results of operations and cash flows for the three ~~and nine~~ month periods ended ~~September 30, 2021~~March 31, 2022 and ~~2020.~~2021.

Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiary, TransBiotec-CA. We have eliminated all intercompany transactions and balances between entities consolidated in these unaudited condensed financial statements.

8
~~Table of Contents~~
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the recoverability and useful lives of long-lived assets, the intellectual technology, the valuation of the derivative ~~liabilities,~~instruments, beneficial conversion feature expenses, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.
9
Table of Contents

Financial Instruments
Pursuant to Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 and 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 and 825 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets: quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist primarily of cash, accounts payable, accrued expenses, accrued interest payable, related party payables, notes payable, convertible debentures, and other liabilities. Pursuant to ASC 820 and 825, the fair value of our derivative liabilities is determined based on “Level 3” inputs. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

The following table presents assets and liabilities that are measured and recognized at fair value as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020:~~2021:

~~September 30, 2021~~

Level 1

Level 2

Level 3

Derivative liability

$ 0

$ 0

$ 980,000

$ 0

$ 0

$ 980,000

~~December 31, 2020~~

Level 1

Level 2

Level 3

Derivative liability

$ 0

$ 0

$ 0

$ 0

$ 0

$ 0

9
~~Table of Contents~~
March 31, 2022

Level 1

Level 2

Level 3

Derivative liabilities

$ 0

$ 0

$ 1,380,000

December 31, 2021

Level 1

Level 2

Level 3

Derivative liabilities

$ 0

$ 0

$ 1,040,000

Cash
The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. The Company does not have any cash equivalents as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020.~~2021.
Accounts Receivable
Accounts receivable is derived from sales to a limited number of customers at March 31, 2022. Customer accounts are monitored for potential credit losses based upon management’s assessment of expected collectability and the allowance for doubtful accounts is reviewed periodically to assess the adequacy of the allowance. In making this assessment, management takes into consideration any circumstances of which the Company is aware regarding a customer’s inability to meet its financial obligations to the Company, and any potential prevailing economic conditions and their impact on the Company’s customers. The Company had no allowance for doubtful accounts at March 31, 2022 and December 31, 2021.
Inventory
Inventory is valued at the lower of cost or net realizable value. The cost of substantially all the Company’s inventory is determined by the FIFO cost method. Inventory is comprised primarily of finished products intended for sale to customers. The Company evaluates the need for reserves for excess or obsolete inventory determined primarily based upon estimates of future demand for the Company’s products. At March 31, 2022 and December 31, 2021 the Company had no reserves for obsolescence.
10
Table of Contents

Prepaid Expenses
Amounts incurred in advance of contractual performance or coverage periods are recorded as prepaid assets and recognized as expense in the period service or coverage is provided.

Beneficial Conversion Features
From time to time, the Company may issue convertible notes that may contain a beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Derivative Instruments
The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instruments are initially recorded at their fair values and are then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated statements of operations under other income (expense). The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option at its fair value as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As a result of entering into warrant agreements, for which such instruments contained a variable conversion feature with no floor, the Company has adopted a sequencing policy in accordance with ASC 815-40-35-12 whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. For stock-based derivative financial instruments, the Company uses a Monte Carlo Simulation model to value the derivative instruments at inception and on subsequent valuation dates.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

10
~~Table of Contents~~
Debt Issuance Costs
Debt issuance costs incurred in connection with the issuance of debt are capitalized and amortized to interest expense over the term of the debt using the effective interest method. The unamortized amount is presented as a reduction of debt on the balance sheet.

Preferred Stock
We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.

~~Minority~~Noncontrolling Interest ~~(Noncontrolling Interest)~~
A subsidiary of the Company has minority members representing ownership interests of 1.38% at ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020.~~2021. The Company accounts for these minority, or noncontrolling interests, pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.
11
Table of Contents
Impairment of Long-Lived Assets
Long-lived assets and identifiable intangibles held for use are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the sum of undiscounted expected future cash flows is less than the carrying amount of the asset or if changes in facts and circumstances indicate, an impairment loss is recognized and measured using the asset’s fair value. No impairment loss was recognized during the three-month periods end March 31, 2022 and 2021.
Revenue Recognition
The Company enters contracts with customers and generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services. Depending on the combination of products and services detailed in the respective customer contract, the identifiable components may be highly interdependent and interrelated with each other such that each is required to provide the substance of the value of SOBR’s offering and accounted for as a combined performance obligation, or the specific components may be generally distinct and accounted for as separate performance obligations. Revenue is recognized when control of these software products and/or services are transferred to the customer in an amount that reflects the consideration the Company expects to be entitled in exchange for these respective services and devices.
Revenue is recognized in conjunction with guidance provided by Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”) issued by the Financial Accounting Standards Board in May 2014. The company determines revenue recognition through five steps outlined in ASC 606 which include (1) the identification of the contract or contracts with a customer, (2) identification of individual or combined performance obligations contained in the contract, (3) determination of the transaction price detailed within the contract, (4) allocation of the transaction price to the specific performance obligations, and (5) finally, recognition of revenue as the Company’s performance obligations are satisfied according to the terms of the contract.
Contracts with a Single License/Service Performance Obligation
For contracts with a single performance obligation consisting of a license and/or data services, the entire transaction price is allocated to the single performance obligation and recognized at a point in time. Where the Company provides a performance obligation as licensed software or data services, revenue is recognized upon delivery of the software or services ratably over the respective term of the contract.
Contracts for Purchase of Hardware Devices Only
Where hardware devices are sold separately by the Company, the entire transaction price is allocated to the device as an individual performance obligation and revenue recognized at a point in time when either legal title, physical possession or control have transferred to the customer. Generally, these requirements are satisfied at the point in time the Company ships the product, as this is when the customer obtains control of the asset under SOBR’s standard terms and conditions of the purchase.
Contracts with Multiple Performance Obligations
Where a Company’s contract with a respective customer contains multiple performance obligations and due to the interdependent and interrelated nature of the licensed software, hardware devices and data reporting services, the Company accounts for the individual performance obligations if they are distinct in nature and the transaction price is allocated to each distinct performance obligations on a directly observable standalone sales price basis. Determining whether products and services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting requires significant judgment. Standalone selling prices are primarily based upon the price at which the performance obligation is sold separately. The Company may be able to establish a standalone sales price based upon observable products or services sold or priced separately in comparable circumstances, competitor pricing or similar customers. Where the performance obligations are either not distinct or directly observable, the Company estimates the standalone sales price of the performance obligations based upon the overall pricing objectives taking into consideration the value of the contract arrangement, number of licenses, number and types of hardware devices and the length of term of the contract. Professional judgement is required to determine the standalone sales price for each performance obligation where not directly observable. Revenue for Contracts with Multiple Performance Obligations is recognized on a ratable basis for each respective performance obligation as allocated under the prescribed Transaction Price identification model applied.
12
Table of Contents
The Company requires customers to make payments related to subscribed software licenses and data services on a monthly basis via authorized bank account ACH withdrawal or an automatic credit card charge during the approved term of the respective agreement. The collectability of future cash flows are reasonably assured with any potential non-payment easily identified with future services being discontinued or suspended due to non-payment.
The Company’s contracts are generally twelve to thirty-six months in duration, are billed monthly in advance and are non-cancelable. The timing of revenue recognition may differ from the timing of invoicing to customers. The Company generally has an unconditional right to consideration when customers are invoiced and a receivable is recorded. A contract asset (unbilled revenue) is recognized when revenue is recognized prior to invoicing, or a contract liability (deferred revenue) when revenue will be recognized subsequent to invoicing.
The Company has elected to charge shipping, freight and delivery to customers as a source of revenue to offset respective costs when control has transferred to the customer.
We report revenue net of sales and other taxes collected from customers to be remitted to government authorities.
Estimated costs for the Company’s standard one-year warranty are charged to cost of products sold when revenue is recorded for the related product. Royalties are also charged to cost of products sold.

Stock-based Compensation
The Company follows the guidance of the accounting provisions of ASC 718, ~~“Share-based Compensation”~~Share-based Compensation, which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants, options, and ~~options)~~restricted stock units). The fair value of each warrant and option ~~award~~ is estimated on the date of grant using the Black-Scholes options pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. The Company has not paid ~~common stock~~ dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the ~~options.~~awards. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its ~~options.~~awards. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of a restricted stock unit equals the closing price of our common stock on the trading day of the grant date.

Research and Development
The Company accounts for its research and development costs pursuant to ASC 730, whereby it requires the Company to disclose the amounts of costs for company and customer-sponsored research and development activities, if material. Research and development costs are expensed as incurred. The Company incurred research and development costs as it acquired new knowledge to bring about significant improvements in the functionality and design of its SOBR product. Research and development costs were ~~$1,026,679~~$47,459 and ~~$309,403~~$171,463 during the ~~nine month~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively.

Advertising and Marketing Costs
Advertising and marketing costs are charged to operations as incurred. Advertising and marketing costs were ~~$70,692~~$30,185 and ~~$70,198~~$26,242 during the ~~nine month~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively, and are included in general and administrative expenses in the consolidated statements of operations.

~~Depreciation~~
Depreciation is computed on a straight-line basis over the assets estimated useful lives of three years. There was no depreciation for the three and nine months ended September 30, 2021. Depreciation for the three and nine months ended September 30, 2020 was $3,978 and $5,083, respectively .
Income Tax
The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not recorded any deferred tax assets or liabilities at ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020~~2021 as these have been offset by a 100% valuation allowance.

1113
Table of Contents

Net Loss Per Share
Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share gives the effect to all dilutive potential common shares outstanding during the period, including stock options, warrants and convertible instruments. Diluted net loss per share excludes all potentially issuable shares if their effect is anti-dilutive. Because the effect of the Company’s dilutive securities is anti-dilutive, diluted net loss per share is the same as basic loss per share for the periods presented.

Concentration of Credit Risk
~~Certain financial instruments potentially subject the Company to concentrations of credit risk.~~ Credit Risk – Financial instruments that potentially subject the Company to concentration of credit risk ~~consist principally~~consisted primarily of cash. The Company maintains its cash ~~deposits. Cash held~~at one domestic financial institution. The Company is exposed to credit risk in ~~operating accounts may exceed~~the event of a default by the financial institution to the extent that cash is in excess of the amount insured by the Federal Deposit Insurance ~~Corporation (“FDIC”) insurance limits. Accounts at each institution are insured by the FDIC up to $250,000. While the~~Corporation. The Company ~~monitors~~places its cash ~~balances in our operating accounts on a regular basis and adjust the balances as appropriate, these balances could be impacted if the underlying~~with high-credit quality financial institutions ~~fail.~~and are managed within established guidelines to mitigate risk. To date, the Company has not experienced noany loss ~~or lack~~on its cash.
Concentration of ~~access~~Customers – The Company has conducted limited sales during the three-months ending March 31, 2022 to ~~our cash; however,~~two customers. Should the Company ~~can provide no assurances that access~~continue to ~~our cash will not be impacted by adverse conditions in the financial markets. At September 30, 2021~~conduct sales to a limited number of customers and ~~December 31, 2020,~~remain highly concentrated, revenue may experience significant period to period shifts and may decline if the Company ~~had $1,934,969~~were to lose one or more of its customers, or if the Company were unable to obtain new customers upon the completion of sales agreements.
Concentration of Suppliers – The Company relies on a limited number of components and ~~none, respectively~~contract suppliers to assemble its product. If supplier shortages occur, or quality problems arise, production schedules could be significantly delayed or costs significantly increased, which could in ~~excess~~turn have a material adverse effect on the Company’s financial condition, results of ~~the FDIC insured limits.~~operations and cash flow.

Related Parties
Related parties are any entities or individuals that, through employment, ownership, or other means, possess the ability to direct or cause the direction of the management and policies of the Company.

~~New Pronouncements~~Recently Issued Accounting Guidance
~~In December 2019, the FASB issued ASU No. 2019-12,~~ ~~Simplifying the Accounting for Income Taxes~~ ~~(“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740,~~ ~~Income Taxes~~,and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is evaluating the effects, if any, of the adoption of ASU 2019-12 guidance on the Company's financial position, results of operations and cash flows.
In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is evaluating the effects, if any, of the adoption of ASU 2020-06 guidance on the Company's financial position, results of operations and cash flows.

~~In October 2020, the FASB issued ASU No. 2020-08,~~ ~~Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs,~~ ~~amendments the guidance in ASU No. 2017-08, (Subtopic 310-20):~~ ~~Premium Amortization on Purchased Callable Debt Securities~~, which addresses multiple call dates of a callable debt security. This amendment is effective for public business entities, for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early application is not permitted. The Company ~~evaluated~~has reviewed other recently issued, but not yet effective, accounting pronouncements and does not believe the ~~adoption~~future adoptions of ~~ASU 2020-08 guidance and determined no effects~~any such pronouncements will be expected to cause a material impact on ~~the Company's~~its financial ~~position,~~condition or the results of ~~operations and cash flows.~~operations.

1214
Table of Contents

~~In May 2021, the FASB issued ASU No. 2021-04,~~ ~~Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments~~ (S~~ubtopic 470-50),~~ ~~Compensation-Stock Compensation~~ ~~(Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity~~ ~~(Subtpoic 815-40)~~, which addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effects, if any, of the adoption of ASU 2021-04 guidance on the Company's financial position, results of operations and cash flows.
~~Correction of Error~~
While preparing financial statements for periods in 2021, the Company discovered an error in the statement of operations for the year ended December 31, 2020. The error related to the presentation of the loss on disposal of property and equipment and asset impairment adjustment in accordance with ASC 360-10-45.
Loss on disposal of property and equipment and asset impairment adjustment of $39,434 and $25,320,555, respectively, were presented as other income/expense-net, instead of as operating expenses. As a result, loss from operations for the year ended December 31, 2020, was understated by $25,359,989 and other income/expenses-net was overstated by the same amount. The errors had no affect on the net loss or net loss per share for the year ended December 31, 2020.
~~As a result of this correction, the statement of operations for the three and nine month periods ended September 30, 2020 in the accompanying financial statements has been retroactively restated.~~
NOTE 2. GOING CONCERN

The Company has incurred recurring losses from operations and has limited cash liquidity and capital resources. Future capital requirements will depend on many factors, including the Company’s ability to sell and develop products, cash flow from operations, and competing market developments. The Company will need additional capital in the near future. Sources of debt financing may result in high interest expense. Any financing, if available, may be on unfavorable terms. ~~If adequate funds are not obtained, we will be required to reduce or curtail operations.~~

As of ~~September 30, 2021,~~March 31, 2022, the Company has an accumulated deficit of approximately ~~$54,200,000.~~($63,000,000). During the ~~nine months~~three-months ended ~~September 30, 2021,~~March 31, 2022, the Company also experienced negative cash flows from operating activities of approximately ~~$2,300,000.~~($775,000). The Company is in default on a $3,048,781 convertible debenture due March 27, 2022 subject to penalties, damages and interest of approximately $1,100,000 (see Notes 8 and 9). It appears these principal conditions or events, considered in the aggregate, indicate it is probable that the Company will be unable to meet its obligations as they become due within one year after the date the financial statements are issued. As such, there is substantial doubt about the entity’s ability to continue as a going concern.

The Company has identified factors that mitigate the probable conditions that have raised substantial doubt about the entity’s ability to continue as a going concern.
On ~~January 15, 2021,~~May 18, 2022, we received approximately $8,779,000 of net proceeds from the ~~Company initiated~~sale of an underwritten public offering of 2,352,942 units (Units) at a ~~Private Offering (the “Offering”)~~public offering price of ~~up to 40 Units ($2,000,000)~~$4.25 per Unit, with each Unit consisting of one ~~$50,000~~share of our Common Stock, par value $0.00001, and two warrants each to purchase one share of Common Stock. The Warrants included in the Units are exercisable immediately and have an exercise price of $4.25 per share (100% of the price per Unit sold in the offering). The Warrants will not be listed for trading and will expire five years from the date of their issuance. On May 19, 2022, the $3,048,781 principal ~~amount secured~~balance of the Armistice Capital Master Fund, Ltd 18% Original Issue Discount Convertible Debenture in default at March 31, 2022, was paid in full satisfying all amounts due and accrued under the default, including penalty, damages and interest provisions of the loan agreement (see Note 16).
Management believes that the net offering proceeds of approximately $5,729,000, after the payment of the defaulted loan balance of $3,048,781, provides adequate working capital for operating activities for the next twelve months after the date the financial statements are issued. However, convertible ~~debenture,~~notes payable plus interest at 12% per annum are due 24 months from issuance. Total principal balances of the convertible notes at March 31, 2022 are $2,005,000 and are due $1,100,000, $155,000 and $750,000 in March 2023, April 2023 and May 2023, respectively. The notes are convertible at $3$9 per share of the Company’s common stock. The notes contain both voluntary and ~~a Warrant to purchase 25,000~~automatic conversion features. The notes may be convertible at any time, by the holders, beginning on the date of issuance. The notes automatically convert into shares of the Company’s common stock if the Company’s common stock closes at $3or above $6 per share. The Secured Debentures carry interest at 12% and mature 24 months after issuance. The Warrants are exercisable six months after issuance and expire 24 months after issuance . The Offering closedshare for five (5) consecutive trading days while listed on ~~May 31, 2021 and raised $2,005,000, see Note 8. On September 28, 2021~~Nasdaq. Should the ~~Company closed~~notes not automatically convert or a significant portion of the sale of a convertible debenture and issued warrants that raised $2,225,000 of net proceeds after debt issuance costs. The debenture is for a face amount $3,048,781 with an OID of 18% and due March 27, 2022, ifnote holders voluntarily not ~~converted, see Note 7.~~
~~We will~~convert the notes to our common stock, we may need additional funds beyond the money raised in ~~this Offering. As a result, we are planning on additional financings in~~ the ~~future.~~underwritten public offering.
13
~~Table of Contents~~

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak and related variants continues to evolve as of the date of this report. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak, its variants and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year ~~2021.~~2022. However, if the pandemic continues, it may have an adverse effect on the Company’s results of future operations, financial position, and liquidity in fiscal year ~~2021.~~2022.

Management believes the net proceeds received from the underwritten public offering and actions presently being taken to ~~obtain additional funding~~generate product and services revenues provide the opportunity for the Company to continue as a going concern; however, these plans are contingent upon actions to be performed by the Company and these conditions have not been met on or before ~~September 30, 2021.~~March 31, 2022. Additionally, the COVID-19 outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown, which ~~would~~could impair the Company’s ability to raise needed funds to continue as a going concern. As such, substantial doubt about the entity’s ability to continue as a going concern was not alleviated as of ~~September 30, 2021.~~March 31, 2022.
15
Table of Contents

NOTE 3. ASSET PURCHASE

On June 5, 2020, the Company completed a transaction (the “Transaction”) with IDTEC subject to the terms and conditions of the APA and that was accounted for as an asset purchase. Pursuant to the APA, IDTEC provided personnel, experience, and access to funding to assist with the development of the SOBR device, as well as sold to us certain robotics assets, which our management believes are synergistic with our current assets, in exchange for 12,000,000 shares of our common stock after giving effect to the reverse stock split effected in connection with closing the Transaction.
As a result of closing the Transaction, the Company issued a convertible promissory note for all the funds spent or advanced by IDTEC prior to closing. This note totaled $1,485,189(the “APA Note”), with simple interest at 10% per annum, due upon demand, and may be convertible into shares of common stock at $0.50 per share (after giving effect to the reverse stock split and subject to anti-dilution protection against any future securities we may issue at an effective price of less than $0.50 per share) at the discretion of the holder. The repayment of APA Note is secured by a first priority security lien or security interest in the patents, trademarks, tradenames, and other intellectual property of the Company.
~~At closing, some of the closing conditions under the APA were either waived and/or modified by the parties. In order to document those modifications and waivers, we entered into a Waiver Under~~ Asset Purchase Agreement and Post-Closing Covenant Agreement with IDTEC. One of the closing conditions that was the subject of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement was the requirement that the Company have under $125,000 in permitted liabilities (not including aged liabilities) after closing of the Transaction. At closing we had approximately $158,000 in non-permitted liabilities under the APA. As a result, the Company issued a Warrant to Purchase Common Stock to IDTEC (the ~~“Warrant”~~“APA”), under which IDTEC will purchase up to 320,000 shares of our common stock (post-split) at an exercise price of $0.50 per share, if either (i) we are forced to pay a non-permitted liability, then we may force IDTEC to exercise the Warrant and pay the exercise price to pay the non-permitted liability, but only in an amount sufficient to pay the non-permitted liability, or (ii) if IDTEC otherwise elects to exercise the Warrant and acquire some or all of the shares underlying the Warrant. The Warrant expires five years after the date of issuance.
. The Transaction, recorded as an asset purchase, was valued at $29,222,955, which consists of the market price as of June 5, 2020 of the Company’s ~~12,000,000~~4,000,000 shares of common stock issued totaling $27,120,000, the value of the APA Note Payable for funds spent by IDTEC and affiliates prior to closing of ~~$1,407,051~~$1,407,501, and the fair value of warrants issued to IDTEC under a Waiver Under Purchase Asset Agreement and Post Closing Covenant Agreement to purchase 106,667 shares of common stock at an exercise price of $1.50 per share which expires five years after the ~~Warrant issued~~date of issuance of $695,454.
In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets such as the analysis of historical financial performance of the products and estimates of future performance of the products and intellectual properties acquired. The allocation to identifiable intangible assets required extensive use of financial information and management's best estimate of fair value.
14
~~Table of Contents~~
The ~~following summarizes~~Company identified and allocated the ~~transaction closing with IDTEC on June 5, 2020:~~value of the asset purchase to intangible assets of $29,175,203 and property and equipment of $47,725.
Property and equipment

$ 47,725

Intangible assets

29,175,230

Total assets

$ 29,222,955

Net purchase (fair value of stock issued, warrants and notes payable)

$ 29,222,955

Subsequent to the Transaction closing, the Company evaluated the fair value of ~~theassets~~the assets acquired based on ~~market estimates for property and equipment and~~ discounted net cash flow for the SOBR Safe intellectual technology. The present value of the discounted cash flow utilized a 75% discount, which included a 25% risk return premium, over an estimated five-year net revenue stream expected to be derived from the technology ~~acquired.~~and market estimates for property and equipment. Based on the assessment of fair value, the Company recognized an asset impairment loss of $25,320,555 ~~resulting from the APA~~ during the year ended December 31, 2020. The impairment was due to the increase of the Company's stock price value. The stock price of the Company at closing of the Transaction was significantly higher than expected from the stock price of the Company when the Company signed the APA. The number of shares to be given to IDTEC as consideration for the Transaction would not get updated for any stock price changes.
Intangible assets

$ 29,175,230

Less: Asset impairment

25,320,555

Intangible assets, net of impairment

$ 3,874,965

NOTE 4. INVENTORY
Inventory at March 31, 2022 and December 31, 2021 consisted of the following:

March 31,

December 31,

2022

2021

Raw materials

$ 51,050

$ 0

Finished goods

53,900

39,461

Inventory, net

$ 104,950

$ 39,461

NOTE 5. PREPAID EXPENSES

Prepaid expenses consist of the following:

September 30,

December 31,

March 31,
2022

December 31,
2021

2021

2020

Consulting service

$ 0

$ 111,860

Rent

20,667

0

Insurance

4,232

3,370

$ 4,286

$ 4,286

Consulting services

25,000

8,267

Prepaid expenses

$ 24,899

$ 115,230

$ 29,286

$ 12,553

On February 26, 2021, the Company entered into a new lease agreement for its office facility for a 12-month term beginning March 1, 2021. In addition to monthly base rent of $6,000, the agreement ~~requires~~required the issuance ~~on 16,000~~of 5,333 shares of its common stock valued at ~~$49,600, all of which has been issued as of September 30, 2021.~~
~~NOTE 5. INTANGIBLE ASSETS~~
~~Intangible assets consist of the following at September 30, 2021:~~

Gross Carrying
Amount

Accumulated
Amortization

Net Intangible
Asset

Amortization
Period (in years)

SOBR Safe Intellectual Technology

$ 3,854,675

$ 513,952

$ 3,340,723

10

~~Amortization~~$49,600. Stock-based compensation expense related to this agreement for the ~~nine-month period ended September 30,~~three-month periods ending March 31, 2022 and 2021 are $8,267 and ~~2020 was $298,098 and $128,488, respectively, and is included in general and administrative expenses in the consolidated statements of operations.~~$4,133, respectively.

15
~~Table of Contents~~
~~Estimated future amortization expense for device technology intangible assets is as follows:~~
2022

2023

2024

2025

   2026

Thereafter

$
385,467

$ 385,467

$ 385,467

$ 385,467

$ 385,467

$ 1,413,388

~~NOTE 6. RELATED PARTY TRANSACTIONS~~
On July 1, 2015, the Company amended a December 3, 2014, note payable agreement with Lanphere Law Group, a related party and shareholder, which forgave $108,000 of a note payable’s principal balance. This debt forgiveness decreased the original principal balance on the note of $214,334 to a new principal balance of $106,335, and a related party gain of $108,000 was recorded to additional paid-in capital. This amendment also extended the note payable’s due date toDecember 2, 2015. The note was converted to common stock during the three months ended March 31, 2020.
On March 8, 2017, Lanphere Law Group irrevocably elected to exercise warrants in order to acquire 969,601 shares of the Company’s common stock in exchange for an aggregate exercise price of $112,871, which was used for the deduction of $74,672 of principal and $38,199 of accrued interest related to the December 3, 2014, note payable agreement with Lanphere Law Group. The forgiveness of the note payable principal of $74,672 was recorded to equity and the $38,199 of related accrued interest was also recorded to equity. The principal balance of the note after the debt deduction was $31,662. On January 3, 2020, the note payable principal balance of $31,662 was converted to 9,520 common shares at a per share price of $3.326.
On January 3, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Michael Lanphere, a beneficial owner of the Company, under which he agreed to exercise warrants and the Company agreed to issue 454,097 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere under two promissory notes. Mr. Lanphere’s option to acquire the shares was under the terms of certain Loan Agreement with Promissory Note and Stock Fees agreements entered into with the Company and Mr. Lanphere on April 17, 2019 and July 17, 2019. The amount of the debt reduction, and therefore the purchase price of the shares, was approximately $66,000 which was used for the deduction of related party notes payable principal of approximately $66,000. 180,397 common shares were issued on January 3, 2020, at an effective conversion price of $0.133 and 273,700 common shares were issued on January 3, 2020 at an effective conversion price of $0.153. After this exercise, Lanphere Law Group owns no warrants for shares of our common stock.
On January 3, 2020, the Company entered into another Debt Conversion and Common Stock Purchase Plan with Michael Lanphere, under which the Company agreed to issue 63,225 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere under numerous other remaining promissory notes. The amount of the debt reduction, and therefore the purchase price of the shares, was $210,285 which was used for the deduction of related party notes payable principal of $169,606 and accrued interest of $40,679. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately $52,000 and accounted for it as additional paid-in capital. The common shares were issued on January 3, 2020 at an effective conversion price of $3.326 per share.
On January 3, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Vernon Justus, a shareholder, under which the Company agreed to issue 84,963 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Justus under a promissory note. The amount of the debt reduction, and therefore the purchase price of the shares, was $282,588 which was used for the deduction of a related party note payable principal of $180,001 and accrued interest of $102,587. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately $70,000 and accounted for it as additional paid-in capital. The common shares were issued on January 3, 2020 at an effective conversion price of $3.326 per share.
On January 16, 2020, the Company entered into a Accounts Payable Conversion and Common Stock Purchase Plan with Michael Lanphere, under which the Company agreed to issue 214,883 shares of its common stock in exchange for a reduction in the amounts owed to Mr. Lanphere for unpaid legal bills. The amount of the debt reduction, and therefore the purchase price of the shares, was $714,700 which was used for the deduction of related party payables of $714,700. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately $222,000 and accounted for it as additional paid-in capital. The common shares were issued on January 16, 2020 at an effective conversion price of $3.326 per share.
16
Table of Contents

~~On January 30, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Devadatt Mishal, one~~NOTE 6. INTANGIBLE ASSETS
Intangible assets consist of the ~~Company’s former directors~~following at December 31, 2021:

Gross
Carrying

Accumulated

Net Intangible

Amortization Period

Amount

Amortization

Asset

(in years)

SOBR Safe

Intellectual Technology

$ 3,854,675

$ 610,318

$ 3,244,357

10

Intangible assets consist of the following at March 31, 2022:

Gross
Carrying

Accumulated

Net Intangible

Amortization Period

Amount

Amortization

Asset

(in years)

SOBR Safe

Intellectual Technology

$ 3,854,675

$ 706,684

$ 3,147,991

10

Amortization expense for the three-month period ended March 31, 2022 and ~~current shareholder, under which the Company agreed to issue 499,965 shares of its common stock~~2021 was $96,366 and $96,366, respectively, and is included in ~~exchange for a reduction~~general and administrative expenses in the ~~amounts owed to Mr. Mishal under numerous promissory notes. The amount~~condensed consolidated statements of the debt reduction, and therefore the purchase price of the shares, was $456,641 which was used for the deduction of related party notes payable principal of $270,300 and accrued interest of $186,341. The Company also recorded a loss on related party debt extinguishment of approximately $144,000. The common shares were issued on January 30, 2020 at an effective conversion price of $0.91465 per share.operations.

On March 23, 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with Prakash Gadgil, one of the Company’s former directors and current shareholder, under which the Company agreed to issue 586 shares of its common stock in exchangeEstimated future amortization expense for a reduction in the amounts owed to Mr. Gadgil under a promissory note. The amount of the debt reduction, and therefore the purchase price of the shares, was $1,950 which was used for the deduction of a related party note payable principal of $1,950. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately $1,000 and accounted for itdevice technology intangible assets is as ~~additional paid-in capital. The common shares were issued on March 23, 2020 at an effective conversion price of $3.326 per share.~~follows:

On April 6, 2020, the Company agreed with Nick Noceti, the Company’s former Chief Financial Officer, to issue 38,437 shares of its common stock in exchange for amounts due for accounting fees. The amount of the debt reduction, and therefore the purchase price of the shares, was $127,840 which was used for the deduction of a related party accounts payable of $127,480. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately $49,000 and accounted for it as additional paid-in capital. The common shares were issued on April 4, 2020 at an effective conversion price of $3.326 per share.
2023

2024

2025

2026

2027

Thereafter

$
385,467

$
385,467

$
385,467

$
385,467

$
385,467

$
1,220,656

On April 7, 2020, the Company agreed with Charles Bennington, one of the Company’s former directors, to issue 6,831 shares of its common stock in exchange for amounts due for Board of Director fees. The amount of the debt reduction, and therefore the purchase price of the shares, was $9,656 which was used for the deduction of a related party accounts payable of $9,656. Based on the fair value of the shares issued, the Company recognized a related party gain of approximately $2,000 and accounted for it as additional paid-in capital. The common shares were issued on April 7, 2020 at an effective conversion price of $1.41 per share.NOTE 7. RELATED PARTY TRANSACTIONS

On February 12, 2021, the Company entered into a note payable agreement with David Gandini, an officer and shareholder, under which Mr. Gandini advanced the Company $30,000 for working capital purposes. The unsecured note carried interest at 0% and was paid in April 2021.

On March 30, 2021, the Company received notification from IDTEC that it was exercising a portion of the ~~320,000~~106,667 warrants issued resulting from the 2020 Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement with IDTEC. The warrant exercise price is ~~$0.50~~$1.50 per share. With the proceeds of the exercise, wethe Company paid $88,469 during the ~~six-month~~three-month period ended ~~June 30,~~December 31, 2021 to settle an outstanding judgement ~~(see Note 14)~~ against the Company which was considered as a non-permitted liability under the Post-Closing Covenant Agreement. We ~~will issue 176,938~~issued 58,980 shares of our common stock for the ~~$88,469~~$88,470 we received from IDTEC to pay the settlement. As the shares had not been issued by ~~June 30,~~March 31, 2021, the amount received from IDTEC iswas included in the common stock subscriptions payable balance at ~~June 30,~~March 31, 2021.

On March 3 and 31, 2021, the Company issued convertible notes payable (see Note 8)10) totaling ~~$450,000~~$350,000 to existing shareholders holding a direct or indirect interest in the Company and ~~$100,000~~$200,000 to a Company’s director and another director’s family member. The principal amount of the secured convertible debentures are convertible at $3$9 per share, and include warrants to purchase in total ~~275,000~~91,667 shares of the Company’s common stock at $3$9 per share.

On May 31, 2021, the Company issued convertible notes payable (see Note 8)10) totaling $400,000 to existing shareholders holding a direct or indirect interest in the Company and $50,000 to a Company’s officer. The principal amount of the secured convertible debentures are convertible at $3$9 per share, and include warrants to purchase in total ~~225,000~~75,000 shares of the Company’s common stock at $3$9 per share.

On March 1, 2022 the Board of Directors approved the designation of 3,000,000 shares of the Company’s Preferred Stock as “Series B Convertible Preferred Stock”. The Series B Convertible Preferred Stock shares were issued in exchange for 1,000,000 shares of the Company’s common stock held by the Company’s CEO David Gandini and 2,000,000 shares of the Company’s common stock held by IDTEC SPV, LLC, an entity controlled by a beneficial owner of the Company (see Note 13).
17
Table of Contents

NOTE 7.8. ACCRUED EXPENSES
Accrued expenses consist of the following:

March 31,
2022

December 31,
2021

Convertible debt default penalty (see Note 9)

$ 914,634

$ 0

Registration rights and default damages and penalties (see Note 9)

192,399

189,663

Consulting services

178,647

163,647

Taxes and other

110,016

110,590

Accrued expenses

$ 1,395,696

$ 463,900

NOTE 9. CONVERTIBLE DEBENTURE PAYABLE

Convertible debenture payable consists of the following:

September 30,
2021

December 31,
2020

   March 31,
2022

December 31,
2021

Convertible Debenture Payable with Detached Free-standing Warrant

$ 3,048,781

$ 0

$ 3,048,781

$ 3,048,781

Unamortized Debt Discount

(2,608,900 )

0

0

(1,291,882 )

Net Convertible Debenture Payable

$ 439,881

$ 0

$ 3,048,781

$ 1,756,899
��

On September 28, 2021, (the “Closing Date”) the Company completed a financing transaction under a Securities Purchase Agreement (the “SPA”) and corresponding 18% Original Issue Discount Convertible Debenture (the “Debenture”), Common Stock Purchase Warrant (the ~~“Warrant”~~“Original Warrant”) and Registration Rights Agreement (“RRA”). Under the terms of the SPA, the Company received $2,500,000 from the Purchaser and in exchange issued the Debenture in the principal amount of $3,048,781 and Original Warrants to purchase up to ~~1,219,512~~406,504 shares of the Company’s common stock. The Debenture is convertible voluntarily by the Purchaser at any time into shares of our common stock, at the lesser of ~~$2.50,~~$7.50, representing 100% of the closing price of our common stock on the trading day immediately prior to the Closing Date, or 75% of the average VWAP of our common stock during the 5 trading day period immediately prior to the conversion date (the “Conversion Price”), or automatically upon the occurrence of a single public offering of our common stock which results in the listing of our common stock on a national securities exchange as defined in the Exchange Act (the “Qualified Offering”) into shares of our common stock at the lesser of the Conversion Price, or 75% of the offering price of the securities offered in the Qualified Offering. The Debenture ~~matures on~~due date is March 27, 2022, does not accrue interest unless there is an event of default under the terms of the Debenture. The Original Warrant is exercisable at any time through September 28, 2026 into shares of our common stock at an exercise price of ~~$2.00~~$6.00 per share, unless an event of default occurs, at which time the exercise price will adjust to ~~$1.00~~$3.00 per share. The Original Warrant contains a cashless exercise provision but only in the event the Company fails to have an effective registration statement registering the common shares underlying the Original Warrant at any time beginning six months from the Closing ~~Date.~~Date The RRA requires the Company to register for resale and maintain effectiveness of such Registration Statement for such all of the registrable securities under the terms of the Debenture and Original Warrant, within defined time frames. Should the Company fail to meet the RRA requirements, until the date causing such event of noncompliance is cured, ~~the~~ Company shall pay to the Purchaser as partial liquidated damages equal to the product of 2% of the principal amount not to exceed 24% of the aggregate principal. If the Company fails to pay of the liquidated damages within seven days after the date payable, the Company will pay interest at 18% until such amounts are paid in full. The filing date requirements were cured in February 2022. Total unpaid RRA damages and estimated related costs of approximately $192,399 and $189,700, are included in accrued expenses at March 31, 2022 and December 31, 2021 (see Note 8). Damage expenses included in general and administrative expenses in the Condensed Consolidated Statement of Operations were $2,736 and none for the three-month periods ended March 31, 2022 and 2021.
18
Table of Contents
The Debenture matured on March 27, 2022 and the Company did not make the required principal payment putting the Company in default under the terms of the Debenture. On March 30, 2022, we entered into a Waiver Agreement with the Purchaser, under which the Purchaser granted the Company a waiver of the default penalties under the Debenture such that any default penalties will not be charged and/or due until April 17, 2022 (the “Waiver”). Default penalties at the Purchaser’s election are due and payable at the Mandatory Default Amount defined as the sum of (a) the greater of (i) the outstanding principal amount of this Debenture, plus all accrued and unpaid interest hereon, divided by the Conversion Price on the date the Mandatory Default Amount is either (A) demanded or otherwise due or (B) paid in full, whichever has a lower Conversion Price, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded or otherwise due or (y) paid in full, whichever has a higher VWAP, or (ii) 130% of the outstanding principal amount of this Debenture, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of this Debenture, As the default had not been cured through the Waiver date, mandatory default penalties of $914,634 are included in general and administrative expense in the Condensed Consolidated Statement of Operations for the three-months ended March 31, 2022 and included in accrued expenses at March 31, 2022 (see Note 8).
In exchange for the Waiver of the default penalties the Company agreed to: (i) amend that certain Common Stock Warrant (the “Original Warrant”) issued by the Company to the Purchaser dated September 27, 2021 to extend the Termination Date (as defined in the Original Warrant) from September 28, 2026 to September 28, 2028; and (ii) issue the Purchaser a second Common Stock Purchase Warrant (the “New Warrant”) entitling the Purchaser to subscribe for and purchase up to an additional 101,626 shares of our common stock, expiring March 29, 2029, with all other terms of the warrant the same as the Original Warrant. We also agreed, within thirty (30) days of the date of the Waiver, to file a Registration Statement on Form S-1 (or, if such form is unavailable for such a registration, on such other form as is available for such registration), covering the resale of all of the shares underlying the New Warrant. As a result of the default event, Debenture’s automatic conversion features upon the occurrence of a Qualified Offering no longer apply and interest accrues at 18% per annum on the principal amount.
The Company evaluated the Debenture for embedded derivative ~~embedded~~ and beneficial conversion features and determined that its embedded conversion feature carried a debt discount. The total conversion feature debt discount of $980,000 is amortized over the life of the convertible debenture. The debt discount amortization expense recorded as amortization of interest in the condensed consolidated statements of operations was ~~$16,245~~$465,635 and none for the ~~nine-month period~~three-month periods ended ~~September 30, 2021.~~March 31, 2022 and 2021, respectively. As of ~~September 30, 2021,~~March 31, 2022, the debenture carries outstanding warrants of ~~1,219,512.~~508,130. The relative fair ~~market~~ value of the related stock warrants granted during the ~~nine month period~~three-month periods ended ~~September 30,~~March 31, 2022 and March 31, 2021 ~~and 2020~~ was ~~$847,048~~$864,000 and none, respectively. The unamortized discount at ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020~~2021 was ~~$833,008~~none and ~~none,~~$402,465, respectively. Stock warrants amortization expense recorded as interest expense was ~~$14,039~~$465,635 and none for the ~~nine month~~three-month periods ended March 31, 2022 and 2021, respectively.
As a result of the change in the Original Warrant extended termination date and the New Warrant issued in exchange for the Waiver, the Company evaluated the reacquisition price of the Debenture under ASC 470-50-40-2 to be $3,912,781. As the net carrying amount of the Debenture is $3,048,781, a loss on extinguishment of debt of $864,000 was recognized during the three-month period ended ~~September 30, 2021.~~ March 31, 2022.
The Company incurred $548,781 of ~~Original Issue Discount~~original issue discount and $275,000 of debt issuance costs related to the Debenture which iswas being amortized to interest expense over the term of the debt using the effective interest method. ~~Interest expense related to the Original Issue Discount and debt issuance costs was $11,645 for the nine month period ended September 30, 2021.~~ The unamortized discount and issuance costs at ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020~~2021 was ~~$812,134~~none and $423,782, respectively. Interest expense related to the original issue discount and debt issuance costs was $423,782 and none for the three-month periods ended March 31, 2022 and 2021, respectively.

1819
Table of Contents

NOTE 8.10. NOTES PAYABLE

RELATED PARTIES

Related party notes payable consist of the following:

    September 30,
      2021

December 31,
2020

    March 31,
2022

December 31,
2021

Convertible Notes Payable with Detached Free-standing Warrants

$ 1,000,000

$ 0

$ 1,000,000

$ 1,000,000

Conventional Non-Convertible Notes Payable

11,810

11,810

11,810

11,810

Unamortized Debt Discount

(771,576 )

0

(522,262 )

(645,547 )
Net Related Party Notes Payable

$ 240,234

$ 11,810

$ 489,548

$ 366,263

Current Portion

(11,810 )

(11,810 )

(302,152 )

(11,810 )
Net Long-Term Portion

$ 228,424

$ 0

$ 187,396

$ 354,453

Total interest expense for related party notes was ~~$55,151~~$385,889 and ~~$79,596~~$3,847 for the ~~nine month period~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively.

Related Party Convertible Notes Payable with Detached Free-Standing Warrants

The Company has thirteen convertible notes payable to related parties, each with detached free-standing warrants to purchase the Company’s common stock at $3$9 per share, that have a total principal balance of $1,000,000 as of ~~September 30, 2021.~~March 31, 2022. The notes, secured by the Company’s patents and patents applications, include interest at 12%, are convertible at $3$9 per share of the Company’s common stock and are due 24 months after issuance. The note holders may elect to have the interest paid in cash monthly or have the interest accrue and be payable on the maturity date. Interest elected to be accrued will be paid in cash or may be converted into shares of our common stock under the same terms as the principal amount on the maturity date. The notes contain both voluntary and automatic conversion features. The notes will be convertible at any time, by the holders, beginning on the date of issuance. However, the holders may not convert any outstanding amounts due under the note if at the time of such conversion the amount of common stock issued for the conversion, when added to other shares of Company common stock owned by the holders or which can be acquired by holders upon exercise or conversion of any other instrument, would cause the holder to own more than 4.9% of the Company’s outstanding common stock. Beginning on the issuance date, the outstanding principal amount of the note, and any accrued interest, will automatically convert into shares of the Company’s common stock if the Company’s common stock closes at or above $6 per share for five (5) consecutive trading days while listed on NASDAQ. The Company evaluated the convertible notes payable for embedded derivative ~~embedded~~ and beneficial conversion features. The Company determined that there were beneficial conversion features to record. The total beneficial conversion feature debt discount of $448,999 is amortized over the life of the convertible notes payable. The debt discount amortization expense recorded as amortization of interest – beneficial conversion feature in the condensed consolidated statements of operations was ~~$101,070for~~$55,356 and $6,361 for the ~~nine-month period~~three-month periods ended ~~September 30, 2021.~~March 31, 2022 and 2021, respectively. The unamortized beneficial conversion feature was $235,986 and $291,343 at March 31, 2022 and December 31, 2021, respectively. As of ~~September 30, 2021,~~March 31, 2022, these notes carry outstanding warrants of ~~500,000.~~166,667. The relative fair ~~market~~ value of the related stock warrants granted during the ~~nine-month period~~three-month periods ended ~~September 30,~~March 31, 2022 and March 31, 2021 was none and ~~2020 was $551,001 and none, respectively. The unamortized discount at September 30, 2021 and December 31, 2020 is $423,647 and none,~~$287,781, respectively. Stock warrants amortization expense recorded as interest expense was ~~$127,354~~$67,932 and $8,981 for the ~~nine-month period~~three-month periods ended ~~September 30, 2021.~~
19
~~Table of Contents~~
~~Related Party Convertible Notes Payable~~
On June 5, 2020 the Company issued the convertible APA Note to a related party with a principal balance of $1,485,189, which included the $70,000 balance of three convertible notes payable to related partiesMarch 31, 2022 and ~~related accrued interest of $7,689 outstanding~~2021, respectively. The unamortized discount at March 31, 2022 and December 31, ~~2019. The note includes simple interest at 10% per annum, due upon demand,~~2021 is $286,274 and may be convertible into shares of common stock at $0.50 per share (after giving effect to the reverse stock split and subject to anti-dilution protection against any future securities we may issue at an effective price of less than $0.50 per share) at the discretion of the holder. The Company evaluated the convertible note payable for derivative embedded and beneficial conversion features. The Company determined that there was a beneficial conversion feature to record. During the year ended December 31, 2020, beneficial conversion feature amortization expense related to this related party convertible note payable of $1,407,675 was accounted for as amortization of interest - beneficial conversion feature expense in the consolidated statements of operations. On November 15, 2020, the related party holder elected to convert the note principal and accrued interest balance of $1,551,514 into 3,103,028 of shares of common stock.$354,205, respectively.

~~Related Party~~Conventional Non-convertible Notes Payable

The Company has one non-convertible note payable to a related party that has a principal balance of $11,810 as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020.~~2021. The note carries an interest rate at 0%. The note payable had a due date of December 31, 2012 and is currently in default.
20
Table of Contents

NON-RELATED PARTIES

Non-related party notes payable consist of the following:

September 30,
2021

December 31,
2020

March 31,
2022

December 31,
2021

Convertible Notes Payable with Detached Free-standing Warrants

$ 1,005,000

$ 0

$ 1,005,000

$ 1,005,000

Convertible Notes Payable

56,683

56,683

9,183

56,683

Conventional Non-Convertible Notes Payable

42,500

42,500

42,500

42,500

Notes Payable with Detached Free-standing Warrants

5,000

5,000

5,000

5,000

Unamortized Debt Discount

(774,850 )

0

(519,571 )

(648,580 )
Net Non-Related Party Notes Payable

$ 334,333

$ 104,183

$ 542,112

$ 460,603

Current Portion

(104,183 )

(79,183 )

(348,508 )

(104,183 )
Net Long-Term Portion

$ 230,150

$ 25,000

$ 193,604

$ 356,420

Total interest expense for non-related party notes was ~~$65,130~~$129,009 and ~~$14,036~~$5,141 for the ~~nine-month~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively.

Convertible Notes Payable with Warrants

The Company has sixteen convertible notes payable to non-related parties, each with detached free-standing warrants to purchase the Company’s common stock at $3$9 per share, that have a total principal balance of $1,005,000 as of ~~September 30,~~March 31, 2022 and December 31, 2021. The notes, secured by the Company’s patents and patents applications, include interest at 12%, are convertible at $3$9 per share of the Company’s common stock and are due 24 months after issuance. The note holders may elect to have the interest paid in cash monthly or have the interest accrue and be payable on the maturity date. Interest elected to be accrued will be paid in cash or may be converted into shares of our common stock under the same terms as the principal amount on the maturity date. The notes contain both voluntary and automatic conversion features. The notes will be convertible at any time, by the holders, beginning on the date of issuance. However, the holders may not convert any outstanding amounts due under the note if at the time of such conversion the amount of common stock issued for the conversion, when added to other shares of Company common stock owned by the holders or which can be acquired by holders upon exercise or conversion of any other instrument, would cause the holder to own more than 4.9% of the Company’s outstanding common stock. Beginning on the issuance date, the outstanding principal amount of the note, and any accrued interest, will automatically convert into shares of the Company’s common stock if the Company’s common stock closes at or above $6 per share for five (5) consecutive trading days while listed on NASDAQ. The Company evaluated the convertible notes payable for derivative embedded and beneficial conversion features. The Company determined that there were beneficial conversion features to record. The total beneficial conversion feature debt discount of $460,215 is amortized over the life of the convertible notes payable. The debt discount recorded as amortization of interest – beneficial conversion feature in the consolidated statements of operations was ~~$105,060~~$59,230 and $3,181 for the ~~nine-month period~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021. As of ~~September 30, 2021,~~March 31, 2022, these notes carry outstanding warrants of ~~502,500.~~167,500. The relative fair ~~market~~ value of the related stock warrants granted during the ~~nine-month period~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021 was none and ~~2020 was~~ $541,707, ~~and none, respectively. The unamortized discount at September 30, 2021 and December 31, 2020 was $419,695 and none,~~ respectively. Stock warrants amortization expense recorded as interest expense was ~~$122,012~~$69,780 and $4,491 for the ~~nine-month period~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021. The unamortized discount at March 31, 2022 and December 31, 2021 was $281,646 and $351,425, respectively.
20
~~Table of Contents~~

Convertible Notes Payable

The Company has two unsecured, convertible notes payable to non-related parties that have a principal balance of $9,183 as of March 31, 2022 and three convertible notes payable to non-related parties that have a principal balance of $56,683 as of ~~September 30, 2021 and~~ December 31, ~~2020.~~2021. These notes carry interest rates ranging from 5% - 12% and have due dates ranging from February 2013 to March 2022. ~~Two~~Notes with principal balances of ~~the three notes~~$9,183 are ~~currently~~ in ~~default.~~default at March 31, 2022 and December 31, 2021. These notes carry a conversion ~~prices ranging from $1.99- $10.7619~~price of $6.00 to $32.29 per share. On March 3, 2022 the Company authorized the issuance of 7,917 shares of common stock under the terms of a $47,500 convertible note payable issued March 6, 2020 with interest at 5%, due March 6, 2022 and convertible at $6.00 per share. The Company evaluated these convertible notes payable for embedded derivative ~~embedded~~ and beneficial conversion features. The Company determined that there were beneficial conversion features to record. The beneficial conversion features were either fully amortized upon grant or over the life of the convertible notes payable. ~~The conversion features were fully amortized prior to 2020.~~
During the three months ended March 31, 2020, the Company entered into Debt Conversion and Common Stock Purchase Plans with six non-related parties, under which the Company agreed to issue 50,135 shares of its common stock in exchange for a reduction of eleven convertible notes payable to non-related parties. The amount of the debt reduction, and therefore the purchase price of the shares, was $166,750 which was used for the deduction of non-related party convertible notes payable principal of $83,953 and accrued interest of $82,797. The Company recorded a non-related party gain on loan extinguishment of approximately $103,000.
During the three months ended March 31, 2020, the Company entered into a non-related party convertible note payable agreement to convert a high interest rate convertible non-related party note payable with a principal balance of $25,000 and accrued interest due of $22,500 to a non-related party convertible note payable of $47,500 that accrues interest at 5%. The note conversion rate is $2 per common share. The Company recorded a loss on non-related party debt extinguishment of $11,697.
During 2020, the holder of a $25,000 convertible promissory note with interest at 30% and accrued interest of $61,875 replaced the carrying amount of the note and its conversion features with a new non-convertible note totaling $25,000 that bears interest at 5%. The Company recorded a gain on non-related party debt extinguishment of $61,875.

Non-convertible Notes Payable

The Company has three unsecured, non-convertible notes payable to non-related parties that have a principal balance of $42,500 as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020.~~2021. These notes carry interest rates ranging from 5% - 10% and have due dates ranging from ~~12/25/~~December 2013 ~~- 6/06/~~to June 2022. Two of the three notes are currently in default.

21
During 2020, the Company entered into a Debt Conversion and Common Stock Purchase Plan with a non-related party, under which the Company agreed to issue 20,313 shares of its common stock in exchange for a reduction of a non-convertible non-related party note payable. The amount of the debt reduction, and therefore the purchase price of the shares, was $67,561 which was used for the deduction of non-related party non-convertible notes payable principal of $3,938 and accrued interest of $63,623. The Company recorded a non-related party gain on loan extinguishment of approximately $14,000.
On May 12, 2020, the Company received proceeds of $41,665 from a commercial bank under the SBA Payroll Protection Loan Program. The loan requires interest at 1% and 18 monthly payments of principal and interest beginning December 5, 2020. Provisions of the SBA Payroll Protection Loan Program allow for portions or all the loan balance to be forgiven should certain criteria be met. On December 7, 2020 the Company was notified that the principal balance and accrued interest of $242 was forgiven, and thus the Company recorded a gain on loan extinguishment of approximately $42,000.
Table of Contents

Notes Payable with Warrants

The Company has one unsecured, note payable with detached free-standing warrants to a non-related party that has a principal balance of $5,000 as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020.~~2021. This note carries an interest rate of 10% and had a due date of ~~9/11/~~September 2014. This note is currently in default. The detached free-standing warrants for this note payable were not exercised by the note holder and expired ~~on May 16,~~in 2019.
21
~~Table of Contents~~

NOTE 9.11. DERIVATIVE LIABILITY

In September 2021, the Company completed a financing transition and received $2,500,000 from the Purchaser and in exchange issued an 18% Original Issue Discount Convertible Debenture in the principal amount of $3,048,781. The debenture includes voluntary and automatic conversion features at a variable conversion prices convertible into the Company’s common shares at an undetermined future date. The Company analyzed the conversion features of the debenture agreement for derivative accounting consideration under ASU 2017-11 (ASC 815-15, Derivatives and Hedging), and determined the embedded conversion features should be classified as a derivative because the exercise price of the convertible note is subject to a variable conversion rate and should therefore be accounted for at fair value under ASC 820, Fair Value Measurements and Disclosures, and ASC 825, Financial Instruments. In accordance with ASC 815-15, the Company bifurcated the conversion feature of the debenture and recorded a derivative liability.

The embedded derivative for the debenture is carried on the Company’s balance sheet at fair value. The derivative liability is marked to market each measurement period and any unrealized change in fair value is recorded as a component of the consolidated statement of operations and the associated fair value carrying amount on the balance sheet was adjusted by the change. The Company fair valued the embedded derivative using a Monte Carlo simulation model based on the following assumptions: (1) expected volatility of 120%, (2) risk-free interest rate of 0.05%, and (3) expected life from 4 to 6 months. On September 28, 2021, the Closing Date of the transaction, the fair value of the embedded derivative was $980,000 and is amortized to interest expense over the term of the Debenture. Utilizing level 3 inputs, the Company ~~did not record~~recorded a fair ~~market~~ value ~~gain or~~ loss of $340,000 for the ~~nine months~~three-month period ended ~~September 30, 2021.~~March 31, 2022. The fair value of the embedded derivative recorded on the balance sheet as a liability was ~~$980,000~~$1,380,000 at ~~September 30, 2021.~~March 31, 2022.
A summary of the activity of the derivative liability is shown below:
Balance at December 31, 2021

$ 1,040,000

Fair value of derivatives issued

0

Fair value adjustments

340,000

Balance at March 31, 2022

$ 1,380,000

NOTE ~~10. STOCK SUBSCRIPTIONS PAYABLE~~
The Company has common stock subscriptions payable due to related parties of $91,613 payable with 193,856 of its common shares at September 30, 2021. The Company has common stock subscriptions payable due to related parties of $111,024 payable with 60,087 of its common shares at December 31, 2020.
~~The Company has common stock subscriptions payable due to non-related parties of $136,433 payable with 87,500 of its common shares at September 30, 2021 and December 31, 2020.~~
~~NOTE 11.~~12. COMMON STOCK

The Company’s common stock transactions for the ~~nine months~~three-months ended ~~September 30, 2020, consist of the following:~~
~~The Company issued 601 shares of its common stock for compensation for services rendered.~~
The Company issued 454,097 shares of its common stock for the conversion of $65,728 of related parties’ debt from $0.1530 to $0.13304 per share pursuant to terms of the convertible promissory notes. 454,097 stock warrants were settled along with the related party debt.
The Company issued 214,883 shares of its common stock for the settlement of related party payables of $714,700. A related party gain of approximately $222,000 was recorded as additional paid-in capital from the stock issuance.
The Company issued 38,323 shares of its common stock for the settlement of accounts payables and accrued expenses of approximately $127,000. The Company recorded a net gain of approximately $27,000 from the stock issuance.
The Company issued 648,739 shares of its common stock to related parties for the conversion of $622,004 of debt from $0.9146 to $3.326 per share. The Company recorded $143,660 of loss on debt extinguishment and a related party gain of $124,291 as additional paid in-capital as a result of the stock issuance.
22
~~Table of Contents~~
The Company issued 70,448 shares of its common stock to non-related parties for the conversion of $65,391 of debt at $3.326 per share. The Company recorded $41,665 of loss resulting from the stock issuance.
The Company agreed to convert 121,072 shares of its common stock at values between $0.5821 to $1.039 per share to non-related parties in exchange for their agreement to settle payable balances of $91,464 owed to them. The conversion was in full satisfaction of all outstanding amounts owed. The Company recorded a non-related party loss of $81,867 as other expense in the consolidated statements of operations.
The Company issued 45,268 shares of its common stock to related parties in exchange for their agreement to settle related party accounts payable of $137,496 owed to them. The shares were issued at a value of $86,739 and recorded a related party gain of $50,741 to additional paid-in-capital.
~~The Company issued 12,000,000 shares of its common stock valued at $2.26 as result of the Transaction with IDTEC (see Note 3).~~
~~The Company’s common stock transactions for the nine months ended September 30,~~March 31, 2021, consist of the following:

The Company issued ~~43,169~~14,390 shares of its common stock to SOBR Safe, LLC, an entity controlled by a beneficial owner of the Company, in full satisfaction of $107,880 of accrued dividends resulting from the December 2020 conversion of the Series A-1 Convertible Preferred Stock into common shares, see Note ~~11.~~13.
The Company’s common stock transactions for the three-months ended March 31, 2022, consist of the following:

The Company issued ~~16,000~~16,667 shares of its common stock ~~valued at $49,600 to its landlord~~for RSUs vested during 2021.
The Company issued 7,917 shares of common stock under the terms of a ~~lease agreement expiring in February 2022.~~ $47,500 convertible note payable.
The ~~amount has been recorded as prepaid expense and amortized monthly over the lease term as general and administrative expense in the consolidated statement~~Company exchanged 1,000,000 shares of ~~operations.~~  common stock for 3,000,000 shares of Series B convertible preferred stock (see Note 13).
22
Table of Contents

NOTE ~~12.~~13. PREFERRED STOCK

On November 20, 2015, the Company’s Board of Directors authorized a class of stock designated as preferred stock with a par value of $0.00001 per share comprising 25,000,000 shares, 3,000,000 shares of which were classified as Series A Convertible Preferred Stock. In each calendar year, the holders of the Series A Convertible Preferred Stock are entitled to receive, when, as and if, declared by the Board of Directors, out of any funds and assets of the Company legally available, non-cumulative dividends, in an amount equal to any dividends or other Distribution on the common stock in such calendar year (other than a Common Stock Dividend). No dividends (other than a Common Stock Dividend) shall be paid and no distribution shall be made with respect to the common stock unless dividends shall have been paid or declared and set apart for payment to the holders of the Series A Convertible Preferred Stock simultaneously. Dividends on the Series A Convertible Preferred Stock shall not be mandatory or cumulative, and no rights or interest shall accrue to the holders of the Series A Convertible Preferred Stock by reason of the fact that the Company shall fail to declare or pay dividends on the Series A Convertible Preferred Stock, except for such rights or interest that may arise as a result of the Company paying a dividend or making a distribution on the common stock in violation of the terms. The holders of each share of Series A Convertible Preferred Stock then outstanding shall be entitled to be paid, out of the Available Funds and Assets, and prior and in preference to any payment or Distribution (or any setting part of any payment or Distribution) of any Available Funds and Assets on any shares of common stock, and equal in preference to any payment or Distribution (or any setting part of any payment or Distribution) of any Available Funds and Assets on any shares of any other series of preferred stock that have liquidation preference, an amount per share equal to the Original Issue Price of the Series A Convertible Preferred Stock plus all declared but unpaid dividends on the Series A Convertible Preferred Stock. A reorganization, or any other consolidation or merger of the Company with or into any other corporation, or any other sale of all or substantially all of the assets of the Company, shall not be deemed a liquidation, dissolution, or winding up of the Company. Shares of the Series A Convertible Preferred Stock are convertible at a 35% discount rate to the average closing price per share of the Company’s common stock (either as listed on a national exchange or as quoted over-the-market) for the last 15 trading days immediately prior to conversion. However, no conversions of the Series A Convertible Preferred Stock to shares of common stock can occur unless the average closing price per share of the Company’s common stock (either as listed on a national exchange or as quoted over-the-market) for the last 15 trading days immediately prior to conversion is at least ~~$1.67.~~$5.01. The shares of Series A Convertible Preferred Stock vote on a one for one basis. The right of conversion is limited by the fact the holder of the Series A Convertible Preferred Stock may not convert if such conversion would cause the holder to beneficially own more than 4.9% of the Company’s common stock after giving effect to such conversion.
23
~~Table of Contents~~

On December 9, 2019, the Company’s Board of Directors created a class of preferred stock designated as 8% Series A-1 Convertible Preferred Stock comprising of 2,000,000 shares. During 2020, the authorized shares were increased to 2,700,000 shares. The rights and preferences of the 8% Series A-1 Convertible Preferred Stock are as follows: (a) dividend rights of 8% per annum based on the original issuance price of $1 per share, (b) liquidation preference over the Company’s common stock, (c) conversion rights into shares of the Company’s common stock at $1 per share (not to be affected by any reverse stock split in connection with the Asset Purchase Agreement with IDTEC), (d) redemption rights such that we have the right, upon 30 days written notice, at any time after one year from the date of issuance, to redeem all or part of the Series A-1 Convertible Preferred Stock for 150% of the original issuance price, (e) no call rights by the Company, and (f) each share of Series A-1 Convertible Preferred Stock will vote on an “as converted” basis.

On December 12, 2019, the Company entered into a Series A-1 Preferred Stock Purchase Agreement (the “SPA”) with SOBR SAFE, LLC (“SOBR SAFE”), a Delaware limited liability company and an entity controlled by a beneficial owner of the Company, under which SOBR SAFE agreed to acquire 1,000,000 shares of our Series A-1 Convertible Preferred Stock in exchange for $1,000,000 (the “Purchase Price”). The Company received the Purchase Price on December 12, 2019.

On May 7, 2020, the Company amended a Convertible Preferred Stock Investment Agreement granting the exclusive right to SOBR SAFE to purchase up to 2,700,000 shares of Series A-1 Convertible Preferred Stock.

23
Table of Contents
On July 2, 2020, the Company executed Amendment No. 2 to the Stock Investment Agreement which provides that the full amount of each dividend due on a dividend payment date, even if not declared, shall be paid to any holder regardless of the date on which the holder acquired the stock.

The Series A-1 Convertible Preferred Stock earns cumulative dividends at a rate of 8% per annum, payable in cash or common stock at the option of the Company on June 30 and December 31 of each year. If paid in common stock, the common stock will be valued at the average of the closing price for the five business days prior to the dividend payment date. The preferred shareholders will participate in any common stock dividends on an as converted basis.   ~~Although no dividends were declared as of September 30, 2020, the Company has accrued dividends payable of $161,880 related to the 8% Series A-1 Convertible Preferred Stock as of September 30, 2020.~~ On December 7, 2020, we sent a Notice of Automatic Conversion and Calculation of Dividend Shares to SOBR SAFE notifying them that under the terms governing the shares of Series A-1 Convertible Preferred Stock the 2,700,000 shares of Series A-1 Convertible Preferred Stock owned by SOBR SAFE automatically converted into ~~2,700,000~~900,000 shares of our common stock. In addition, as a result of the conversion of the Series A-1 Convertible Preferred Stock we owed SOBR SAFE accrued dividends totaling $107,880, which we could pay in cash or in shares of our common stock based on the price of common stock on the applicable dividend dates. Our management and Board of Directors elected to pay SOBR SAFE the accrued dividends in shares of our common stock.

24
On March 1, 2022 the Board of Directors approved the designation of 3,000,000 shares of the Company’s Preferred Stock as “Series B Convertible Preferred Stock”. The 3,000,000 Series B Convertible Preferred Stock shares were issued in exchange for 333,333 shares of the Company’s common stock held by the Company’s CEO David Gandini and 666,667 shares of the Company’s common stock held by IDTEC SPV, LLC, an entity controlled by a beneficial owner of the Company. The Company entered into the Share Exchange Agreements to provide certain changes to its capital structure in connection with the planned underwriting offering and listing on Nasdaq. The rights and preferences of the Series B Convertible Preferred Stock are as follows: (a) dividends shall not be mandatory or cumulative, (b) liquidation preference over the Company’s common stock, (c) each three shares of Series B Convertible Preferred Stock shall be convertible, at the option of the holder, beginning on the date that is six months from the date the Holder acquired the shares of Series B Convertible Preferred Stock, and without the payment of additional consideration by the holder , into one share of common stock, (d) no redemption rights by the Company, (e) no call rights by the Company, and (f) each share of Series B Convertible Preferred Stock will vote on an “as converted” basis. As the convertible preferred stock contain voting rights and other comparable features to the common stock it was exchanged for, the exchange resulted in no transfer of value from the common stockholders to the preferred stockholders as included in the condensed consolidated statement of changes in stockholders deficit for the three months ended March 31, 2022.
~~Table of Contents~~

NOTE 1314. STOCK WARRANTS, ~~AND~~ STOCK OPTIONS
~~Stock Warrants~~ AND RESTRICTED STOCK UNITS

The Company accounts for ~~employee~~share-based compensation stock options and restricted stock units, and non-employee stock warrants under ASC 718, ~~and ASC 505,~~ whereby ~~option~~ costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable, utilizing the Black-Scholes pricing ~~model.~~model for stock options and warrants, and the closing price of our common stock on the grant date for restricted stock units. Unless otherwise provided for, the Company covers ~~option~~equity instrument exercises by issuing new shares.

~~On August 8, 2019, the Company entered into an 8% Series A-1 Convertible Preferred~~ Stock Investment agreement with First Capital Ventures, LLC (“FCV”), an entity controlled by a beneficial owner of the Company. FCV set up a special purpose vehicle (“SPV”) or SOBR SAFE, LLC, an entity controlled by a beneficial owner of the Company, that purchased 1,000,000 of the 8% Series A-1 Convertible Preferred Shares at $1 per share on December 12, 2019. Upon purchase, the Company issued the SPV through FCV a three-year warrant to purchase 144,317 shares of the Company’s common stock at an exercise price of $1.039375 per share. The number of warrants outstanding to the SPV through FCV at September 30, 2021 and December 31, 2020 are 144,317.
On May 4, 2020, the Company entered into an agreement with a vendor to provide investor relations services. Under the terms of the agreement, we issued warrants to purchase up to 120,000 shares of our common stock at an exercise price of $2.00 per share. The warrants expire five years after the date of issuance. Approximately $220,000 of expense was recognized for the warrants issued for the services provide by the vendor.
On June 5, 2020, at closing of the Transaction, the Company entered into a Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement under which we issued warrants to IDTEC to purchase up to 320,000 shares of our common stock (post-split) at an exercise price of $0.50 per share. The warrants expire five years after the date of issuance.Warrants

During March, April and May 2021, the Company issued through the Offering convertible notes payable with warrants, ~~see~~(see Note 8,10), to purchase up to ~~1,002,500~~334,167 shares of our common stock at an exercise price of $3$9 per share. The warrants expire two years after the date of issuance.

On September 28, 2021 ~~the Closing Date,~~and March 30, 2022 the Company issued through the sale of the Debenture ~~warrants, see~~Original Warrants and New Warrants, (see Note 7,9), to purchase up to ~~1,219,512~~406,504 and 101,626, respectively, shares of our common stock at an exercise price of $2$6 per share. The warrants expire ~~five~~seven years after the date of issuance.
24
Table of Contents

The total outstanding balance of all stock warrants in the Company is ~~2,629,391~~938,090 and ~~584,317~~836,464 at ~~September 30, 2021~~March 31, 2022 and December 31 ~~2020,~~2021, respectively. There were ~~2,222,012~~101,626 detached free-standing stock warrants granted during the ~~nine month~~three-month period ended ~~September 30, 2021,~~March 31, 2022, and ~~320,000~~183,333 detached free-standing stock warrants granted during the ~~nine month~~three-month period ended ~~September 30, 2020.~~March 31, 2021. The fair value of these non-employee stock warrants granted during the ~~nine-month~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021 totaled $700,000 and ~~2020 totaled $1,939,756 and $695,454,~~$619,381, respectively, and were determined using the Black-Scholes option pricing model based on the following assumptions:

September 30,
2021

September 30,
2020

Exercise Price

$
3.00-2.00

$ 0.50

Dividend Yield

0 %

0 %
Volatility

158-120
%

153 %
Risk-free Interest Rate

0.14%-0.98
%

0.29 %
Life of Warrants

2-5 Years

   5 Years

25
~~Table of Contents~~

March 31,
2022

March 31,
2021

Exercise Price

$ 6.00

$ 9.00

Dividend Yield

0 %

0 %
Volatility

110 %

158 %
Risk-free Interest Rate

2.45 %

0.14 %
Life of Warrants

7 Years

2 Years

The following table summarizes the changes in the Company’s outstanding warrants during the ~~nine-month~~three-month period ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ and as of ~~September 30, 2021~~March 31, 2022 and ~~2020:~~2021:

Warrants
Outstanding
Number of
Shares

Exercise Price Per
Share

Weighted Average Remaining Contractual Life

Weighted Average
Exercise Price Per Share

Aggregate Intrinsic Value

Warrants
Outstanding
Number of
Shares

Exercise
Price Per
Share

Weighted Average Remaining Contractual Life

Weighted
Average
Exercise Price
Per Share

Aggregate
Intrinsic
Value

Balance at December 31, 2019

598,414

$
0.13304–1.039375

3.97 Years

$ 0.3607

$ 1,276,870

Balance at December 31, 2020

194,772

$
1.50 – 6.00

3.80 Years

$ 2.82

$ 1,173,737

Warrants Granted

320,000

$ 0.50

4.68Years

$ 0.50

$ 761,000

183,333

$ 6.00

1.96 Years

$ 9.00

$ 66,000

Warrants Exercised

(454,097 )

$
0.13304 - 0.15299

$ 0.1451

(58,979 )

$ 1.50

0.50 Years

$ 1.50

Warrants Expired

-

-

Balance at September 30, 2020

464,317

$
0.50- 1.039375

3.91 Years

$ 0.66765

$ 1,027,234

Balance at March 31, 2021

319,126

$
1.50 – 6.00

2.52 Years

$ 6.62

$ 875,493

Warrants
Outstanding
Number of
Shares

Exercise Price Per
Share

Weighted Average Remaining Contractual Life

Weighted Average
Exercise Price Per Share

Aggregate Intrinsic Value

Balance at December 31, 2020

584,317

$
0.50 – 2.00

3.80 Years

$ 0.9413

$ 1,173,737

Warrants Granted

2,222,012

$
3.00-2.00

3.40 Years

$ 2.45

$ 108,506

Warrants Exercised

(176,938 )

$ 0.50

$ 0.50

Warrants Expired

-

Balance at September 30, 2021

2,629,391

$
0.50 – 3.00

3.30 Years

$ 2.25

$ 665,424

Warrants
Outstanding
Number of
Shares

Exercise
Price Per
Share

Weighted
Average
Remaining Contractual Life

Weighted
Average
Exercise
Price Per Share

Aggregate Intrinsic Value

Balance at December 31, 2021

836,464

$
1.50 – 9.00

3.04 Years

$ 6.78

$ 1,784,838

Warrants Granted

101,626

$ 6.00

7.00 Years

$ 6.00

$ 152,439

Warrants Exercised

-

$ 0

$ 0

$ -

Warrants Expired/Forfeited

-

$ -

$ 0

$ -

Balance at March 31, 2022

938,090

$
1.50 – 9.00

4.14 Years

$ 6.69

$ 757,863

~~Stock Options~~Share-Based Compensation

On October 24, 2019, the Company’s 2019 Equity Incentive Plan (the “Plan”)went ~~effective.~~effective authorizing 1,282,823 shares of Company common stock for issuance as stock options and restricted stock units (“RSUs”) to employees, directors or consultants. The ~~plan~~Plan was approved by the Company’s Board of Directors and the holders of a majority of the Company’s voting stock on September 9, 2019. In January 2022, the stockholders ratified a further authorization of shares of common stock for a total of 1,733,333 shares subject to the Plan.
The ~~plan’s number~~Company generally recognizes share-based compensation expense on the grant date and over the period of ~~authorized shares is 3,848,467.~~ vesting or period that services will be provided.
Stock Options
As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, the Company has granted stock options to acquire ~~2,921,861~~1,106,587 and ~~2,521,921~~1,036,588 shares of common stock under the plan, respectively. As of ~~September 30, 2021,~~March 31, 2022, the plan has ~~1,893,347~~679,204 vested shares and ~~1,028,514~~427,383 non-vested shares. As of December 31, ~~2020,~~2021, the plan had ~~1,202,724~~618,841 vested shares and ~~1,319,197~~417,747 non-vested shares. ~~As of September 30, 2021 and December 31, 2020 the plan has options available to be issued of 926,606 and 1,326,546, respectively.~~ The stock options are held by our officers, directors, employees, and certain key consultants.

25
Table of Contents
In total for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ the Company recorded ~~$630,027~~in general and ~~$343,549,~~administrative expense $492,441 and $105,013, respectively, of share-based compensation expense related to stock ~~options and restricted stock units.~~options. The unrecognized compensation expense as of ~~September 30, 2021,~~March 31, 2022, was approximately ~~$813,000~~$2,142,569 for non-vested share-based awards to be recognized over periods of approximately ~~one~~two months to three years.
26
~~Table of Contents~~

In applying the Black-Scholes options pricing model, assumptions used to compute the fair value of the stock options granted during the ~~nine-month period~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021 ~~and 2020~~ were as follows:

September 30,
2021

September 30,
2020

Exercise Price

$
2.50 - $3.58

$
0.26-$3.30

Dividend Yield

0 %

0 %
Expected Volatility

44% - 185
%

153%-171
%
Risk-free Interest Rate

0.16% - 1.69
%

0.19%-0.43
%
Expected Life

1.3 - 7 years

2.2-5 years

March 31,
2022
March 31,
2021
Exercise Price
$
8.25 – 9.0750
-
Dividend Yield
0 %
-
Volatility
191%-192
%
-
Risk-free Interest Rate
0.78%-1.52
%
-
Life of Warrants
2 – 3 Years
-

The following table summarizes the changes in the Company’s outstanding stock options during the ~~nine-month period~~three-month periods ended ~~September 30, 2021~~March 31, 2022 and ~~2020, and as of September 30, 2021 and 2020:~~2021:

Options
Outstanding
Number of
Shares

Exercise Price Per
Share

Weighted Average Remaining Contractual Life

Weighted Average
Exercise Price Per Share

Aggregate
Intrinsic Value

Options
Outstanding
Number of
Shares

Exercise
Price Per
Share

Weighted Average Remaining Contractual Life

Weighted
Average
Exercise
Price Per Share

Aggregate
Intrinsic Value

Balance at December 31, 2019

2,381,239

$
0.2634-1.039

8.86 Years

$ 0.2948

$ 5,238,080

Balance at December 31, 2020

857,409

$
0.7902 – 9.90

7.45 Years

$ 1.4997

$ 6,302,277

Options Granted

160,000

$
0.26341-3.30

4.10 Years

$ 1.9454

$ 149,532

-

Options Exercised

-

-

Options Cancelled

-

Options Expired

-

-

Balance at September 30, 2020

2,541,239

$
0.2634 – 3.30

7.86 Years

$ 0.3987

$ 6,305,579

Balance at March 31, 2021

857,409

$
0.7902 – 9.90

7.21 Years

$ 1.4497

$ 6,739,385

Options
Outstanding
Number of
Shares

Exercise Price Per
Share

Weighted Average Remaining Contractual Life

Weighted Average
Exercise Price Per Share

Aggregate Intrinsic Value

Balance at December 31, 2020

2,572,227

$
0.2634–3.300

7.45 Years

$ 0.4999

$ 6,302,277

Options Granted

610,526

$
2.50–3.575

2.58 Years

$ 3.1783

$ (414,147 )
Options Exercised

-

Options Cancelled

(210,587 )

$
0.2634-3.29

$ 2.969

Options Expired

-

Balance at September 30, 2021

2,972,166

$
0.2634–3.575

6.15 Years

$ 0.8751

$ 4,829,417

Options
Outstanding
Number of
Shares

Exercise
Price Per
Share

Weighted Average Remaining Contractual Life

Weighted
Average
Exercise
Price Per Share

Aggregate
Intrinsic Value

Balance at December 31, 2021

1,053,356

$
0.7903 – 10.74

6.21 Years

$ 3.3900

$ 5,804,517

Options Granted

70,000

$
8.25 – 9.0750

2.04 Years

$ 8.2893

$ 0
Options Exercised

-

Options Expired/Forfeited

-

Balance at March 31, 2022

1,123,356

$
0.7903 – 10.7250

5.71 Years

$ 3.7042

$ 2,014,970

Exercisable at December 31, 2020

1,253,030

$
0.2634 – 3.300

7.4 Years

$ 0.3165

$ 3,299,765

Exercisable at September 30, 2021

1,943,652

$
0.2634 – 3.575

6.3 Years

$ 0.6527

$ 3,590,430

Options
Outstanding
Number of
Shares

Exercise Price Per
Share

Weighted Average Remaining Contractual Life

Weighted Average
Exercise Price Per Share

Aggregate Intrinsic Value

Exercisable at December 31, 2021

635,609

$
0.7903 - 10.74

6.7 Years

$ 1.5861

$ 4,655,089

Exercisable at March 31, 2022

695,973

$
0.7903 – 10.73

4.16 Years

$ 2.1692

$ 3,710,124

26
Table of Contents
Restricted Stock Units
The Plan provides for the grant of RSUs. RSUs are settled in shares of the Company’s common stock as the RSUs become vested. In January and February 2022, the Company granted 16,667 service based RSUs to an executive officer and 25,000 service based RSUs to a director, respectively. All RSUs granted in 2022 vest the earlier of the expiration of any lock-up period that includes the securities of the Company owned by the Plan participant after the up list of the Company to a national exchange or January 1, 2023. On January 12, 2022, 16,667 shares of the Company’s common stock were issued for the RSUs vested during 2021.
The following table summarizes RSU activity under the Plan for the three-month periods ended March 31, 2022 and 2021:

RSUs

Weighted Average
Grant Date Fair Value Per Share

Weighted Average
Vesting Period

Unvested at December 31, 2020

71,667

$ 8.75

1.70 Years

Granted

-

Vested

-

Unvested at March 31, 2021

71,667

$ 8.75

1.45 Years

RSUs

Weighted Average
Grant Date Fair Value Per Share

Weighted Average
Vesting Period

Unvested at December 31, 2021

133,585

$ 8.56

0.97 Years

Granted

41,667

6.92

1.01 Years

Vested

-

Unvested at March 31, 2022

175,252

$ 8.17

0.74 Years

In total for the three months ended March 31, 2022 and 2021, the Company recorded in general and administrative expense $442,784 and $60,531, respectively, of share-based compensation expense related to restricted stock units. As of March 31, 2022, total estimated compensation costs of RSUs granted and outstanding but not yet vested was $774,765 which is expected to be recognized over the weighted average period of 9 months.

Executive Officers Stock Options and RSUs

The Company has ~~1,553,152~~311,436 and ~~981,771~~823,482 outstanding executive officers stock options exercisable at ~~$0.2634~~$0.7902 to ~~$3.38~~$10.14 and $0.7902 to $10.14 per share as of ~~September 30, 2021,~~March 31, 2022 and December 31, ~~2020,~~2021, respectively. The Company has 175,252 and 61,919 unvested RSUs granted to executive officers as of March 31, 2022 and December 31, 2021, respectively.

27
Table of Contents

NOTE ~~14.~~15. COMMITMENTS AND CONTINGENCIES

Operating Leases
On October 15, 2019, the Company entered into a short-term lease agreement that is between $2,800 - $2,900per month and ended on October 31, 2020. The lease has been renewed for another twelve months under the same general terms and conditions. The lease was subsequently canceled to accommodate additional space, and a new lease was executed February 26, 2021 the Company executed an office lease, effective for a 12-month term beginning March 1, 2021. The lease requires monthly base rent payments of $6,000 and the issuance of ~~16,000~~5,333 shares of the Company’s common stock. The value of the common stock of $49,600 is amortized to rent expense on a monthly basis over the lease term. This lease was not renewed. The Company leases shared office space on two-to-three-month basis with monthly rents approximating $4,500. The Company also leases an office space for approximately ~~$3,500~~$5,000 per month on a short-term (month to month) basis through a related party that terminates at any time. Rent expense under office leases, including CAM charges, was ~~$106,997~~$48,819 and ~~$47,711~~$23,629 for the ~~nine-month period~~three-month periods ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively.

Legal Proceedings
On December 6, 2006, Orange County Valet and Security Patrol, Inc. filed a lawsuit against usthe Company in Orange County California State Superior Court for Breach of Contract in the amount of $11,164. A default judgment was taken against usthe Company in this matter. In mid-2013 we learned the Plaintiff’s perfected the judgment against ~~us,~~the Company, but we have not heard from the Plaintiffs as of the date of this report. As of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, the Company has accrued ~~$11,164~~11,164 plus accrued interest of approximately ~~$18,000.~~18,000. In the event we pay any money related to this lawsuit, IDTEC agreed ~~in connection with us closing the asset purchase transaction with IDTEC,~~ to pay the amount for usthe Company in exchange for shares of our common stock.

We had one outstanding judgment against us involving a past employee of the Company. The matter was under the purview of the State of California, Franchise Tax Board, Industrial Health and Safety Collections. We owed $28,786 plus accrued interest of approximately $53,000, which had been accrued as of December 31, 2020, to our ex-employee for unpaid wages under these Orders. On March 8, 2021 we received an Acknowledgement of Satisfaction of Judgement-Full by the California Court that the judgement has been settled with a payment of approximately $85,000 including accrued interest through settlement date and legal fees of approximately $3,000. IDTEC agreed, in connection with us closing the asset purchase transaction with IDTEC, to pay the amounts for us in exchange for shares of our common stock.
NOTE ~~15.~~16. SUBSEQUENT EVENTS

The Company has evaluated subsequent events for recognition and disclosure through ~~November 15, 2021,~~May 23, 2022, which is the date the condensed consolidated financial statements were available to be issued.
Our Common Stock has been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the symbol “SOBR” and began trading the exchange on May 16, 2022.
In concert with our up listing to Nasdaq, on May 18, 2022, we received approximately $8,779,000 of net proceeds from the sale of an underwritten public offering of 2,352,942 units (Units) at a public offering price of $4.25 per Unit, with each Unit consisting of one share of our Common Stock, par value $0.00001, and two warrants each to purchase one share of Common Stock. The Units have no stand-alone rights and will not be certified or issued ~~and has determined that there are no other material subsequent events that require recognition or disclosure~~as stand-alone securities. The Warrants included in the ~~accompanying condensed consolidated financial statements.~~Units are exercisable immediately and have an exercise price of $4.25 per share (100% of the price per Unit sold in the offering). The Warrants will not be listed for trading and will expire five years from the date of their issuance.
On May 19, 2022, the $3,048,781 principal balance of the Armistice Capital Master Fund, Ltd 18% Original Issue Discount Convertible Debenture, which was in default at March 31, 2022, was paid in full satisfying all amounts due and accrued under the default including penalty, damages and interest provisions of the debt agreement.

28
Table of Contents

ITEM 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

Disclaimer Regarding Forward Looking Statements

~~Our Management’s Discussion~~This Quarterly Report on Form 10-Q includes a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and ~~Analysis or Plan~~Section 21E of ~~Operations contains not only statements~~the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) that ~~are historical facts, but also statements that are forward-looking. Forward-looking~~reflect management’s current views with respect to future events and financial performance. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by ~~their very nature, uncertain~~the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in,speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the ~~failure~~negative of these terms and similar expressions as they relate to ~~comply~~the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with ~~government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations~~respect to future events and ~~difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability~~are subject to ~~attract and retain qualified personnel; the ability to protect technology;~~risks, uncertainties, assumptions, and other factors, including the risks ~~that might be detailed~~relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from ~~time to time in our filings with the Securities and Exchange Commission (“SEC”).~~those anticipated, believed, estimated, expected, intended, or planned.

Although the ~~forward-looking statements~~Company believes that the expectations reflected in ~~this Quarterly Report reflect~~ the ~~good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because~~ forward-looking statements are ~~inherently subject~~reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to ~~risks~~update any of the forward-looking statements to conform these statements to actual results.
Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and ~~uncertainties,~~assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report. The forward-looking statements made in this report are based only on events or information as of the date on which the statements are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report and have filed as exhibits to this report completely and with the understanding that our actual future results ~~and outcomes~~ may ~~differ~~be materially different from what we expect.
Although we believe that the ~~results and outcomes discussed~~expectations reflected in the forward-looking ~~statements. You~~statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission (“SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as ~~we attempt to advise interested parties of the risks~~required by law. We believe that our assumptions are based upon reasonable data derived from and ~~factors that may affect~~known about our business ~~financial condition,~~ and operations. No assurances are made that actual results of operations ~~and prospects.~~or the results of our future activities will not differ materially from our assumptions.

~~Reverse Stock Split~~
AtAs used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the ~~open of market on June 8, 2020, our 1-for-33.26 reverse split of our common stock went effective with OTC Markets. As a result, all common stock share amounts, as well as share amounts~~terms “Company,” “we,” “us,” and ~~exercise and conversion prices in derivative security instruments have been adjusted~~“our” refer to ~~reflect the reverse stock split.~~
~~Overview~~
We intend to create substance-free environments by integrating and commercializing critical substance detection technologies. These technologies will be integrated within our robust and scalable data platform producing statistical analytics and predictive user data. Our mission is to save lives, accelerate intervention, increase productivity, create significant economic benefit and positively impact behavior. To that end, we developed the scalable, patented SOBRSafe™ software platform for non-invasive alcohol detection and identity verification, a solution that has anticipated applications in school buses, commercial vehicle fleets and facility access control, as well as addiction treatment and managed care.
Currently, our plan is to deploy our SOBRSafe™ technology in two initial devices: the SOBRtab™ wearable band and the SOBRCheck™ system. SOBRtab™ is a transdermal, alcohol-detecting wearable band containing our SOBRSafe™ technology for ongoing, real-time alcohol monitoring, with predictive heart rate monitoring. SOBRCheck™ is our centralized access control product. When installed in manufacturing facilities, warehouses and more, SOBRCheck™ enables a rapid, hygienic finger scan, with real-time results delivered securely to the employer for any necessary corrective action. The SOBRSafe™ technology can also be deployed across numerous additional devices for various uses. Currently, additional devices for our SOBRSafe™ alcohol detection technology we are exploring include possible integrations with existing law enforcement technologies to enhance public safety. In addition, we are proactively evaluating other emerging detection technologies for alcohol, cannabis, opioids, human health and more.SOBR Safe, Inc.

29
Table of Contents

Statistical analytics and predictive user data is another potential valuable asset. We believe our device portfolio approach could yield this highly valuable information asset. The opportunity to collect millions of data points over time could enable the development of predictive analytics for perpetual safety improvement (and associated cost savings capture). And by demonstrating substance-free environments, employers could deliver a data-driven argument for lowering insurance premiums and we could potentially partner with insurance providers to mandate use of the SOBRSafe™ devices and/or technology.
In addition to focusing on the development, marketing and commercialization of the SOBRCheck™ and SOBRtab™ devices, we are also constantly reviewing synergistic technologies and businesses for potential partnerships, including licensing of the SOBRSafe™ technology.Reverse Stock Split

On ~~June 5, 2020, we closed the transaction (the “Transaction”) that was the subject~~November 4, 2021, our Board of ~~that certain Asset Purchase Agreement dated May 6, 2019 (and Amendment No. 1 dated March 9, 2020, together the “APA”) with IDTEC, LLC (“IDTEC”), under which IDTEC agreed~~Directors approved an amendment to ~~provide personnel, experience, and access~~our Articles of Incorporation to funding to assist with the development of our SOBR device, as well as to sell to us certain robotics assets, which our management believes are synergistic with our current assets, in exchange for 12,000,000 shares of our common stock after giving effect to the reverse stock split effected in connection with closing the transaction. The closing of the Transaction was subject to several conditions precedent, primarily: (i) we had to be current in our reporting requirements under the Securities Exchange Act of 1934, as amended, (ii) we had to completeaffect a reverse stock split of our outstanding common stock ~~such that approximately 8,000,000 shares were outstanding immediately prior to closing the transaction, (iii) we could only have outstanding convertible instruments as set forth~~at a ratio between of 1-for-2 and 1-for-3 in ~~the APA, (iv)~~connection with our authorized common stock had to be reduced to 100,000,000 shares, and (v) we could not have more than approximately $125,000 in current liabilities. Effective with the closing of the transaction all of the closing conditions had been met, modified or waived by IDTEC, and we issued the 12,000,000 shares to IDTEC in exchange for IDTEC providing access to personnel, experience, funding to assist with the development of our SOBR device, as well as the robotics assets. The description of the APA set forth in this report is qualified in its entirety by reference to the full text of that document and the amendment, which are attached hereto as Exhibits 10.1 and 10.12, respectively.planned listing on Nasdaq.

~~In advance~~On January 7, 2022, our stockholders approved the same amendment to our Articles of ~~closing~~Incorporation to affect a reverse stock split of our outstanding common stock at a ratio between of 1-for-2 and 1-for-3 in connection with our planned listing on Nasdaq, with the ~~Transaction, IDTEC~~final ratio to be determined by our Board of Directors.
On March 4, 2022, our Board of Directors approved the reverse split ratio of 1-for-3.
On April 28, 2022, the 1-for-3 reverse stock split went effective with the State of Delaware, Financial Industry Regulatory Authority (“FINRA”) and a few other affiliated parties (i) loaned funds directly to us, (ii) spent funds for the general costs related to the transaction, and/or (iii) spent funds to further develop and enhance the current SOBR product.OTC Markets. As a result of ~~closing~~ the ~~transaction, all the funds spent by IDTEC for any reason related~~1-for-3 reverse stock split, every three shares of our outstanding common stock prior to the ~~transaction~~effect of that amendment were ~~turned~~combined and reclassified into ~~a convertible promissory note. The note totaled approximately $1,500,000 at closing, carry a simple interest rate~~one share of ~~10% per annum, are due upon demand,~~our common stock, and ~~may be convertible into~~the number of outstanding shares of our common stock at ~~$0.50 per share (after giving effect~~the time was reduced from 23,409,415 (pre-split) to approximately 7,803,139 (post-split). No fractional shares were issued in connection with the reverse stock split, and ~~subject~~any of our stockholders that would have been entitled to ~~anti-dilution protection against any future securities we may issue at an effective price of less than $0.50 per share) at the discretion~~receive a fractional share as a result of the holder. The promissory note is due on demand of the holder. The repayment of this promissory note is secured by a first priority security lien or security interest in our patents, trademarks, tradenames and other intellectual property described in Exhibit A of the promissory note. The convertible promissory notes we issued are in the form attached hereto as Exhibit 10.13.
As noted above, in connection with the closing of the Transaction, both companies had certain closing conditions under the APA that had to be met. At closing, some of the closing conditions under the APA were either waived and/or modified by the parties. In order to document those modifications and waivers, we entered into a Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement with IDTEC. The description of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement set forth in this report is qualified in its entirety by reference to the full text of that document, which is attached hereto as Exhibit 10.14.
One of the closing conditions that was the subject of the Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement was the requirement that we have under $125,000 in permitted liabilities (not including aged liabilities) after closing of the Transaction. At closing we had approximately $158,000 in non-permitted liabilities under the APA. As a result, we issued a Warrant to Purchase Common Stock to IDTEC (the “Warrant”), under which IDTEC will purchase up to 320,000 sharesreverse stock split instead received one additional share of our common stock (post-split) at an exercise price of $0.50 per share, if either (i) we are forced to pay a non-permitted liability, then we may force IDTEC to exercise the Warrant and pay the exercise price to pay the non-permitted liability, but only in ~~an amount sufficient to pay the non-permitted liability (which are listed on Exhibit A~~lieu of the ~~Warrant), or (ii) if IDTEC otherwise elects to exercise the Warrant and acquire some or all~~fractional share. The reverse stock split did not in itself affect any stockholder’s ownership percentage of ~~the shares underlying the Warrant. The Warrant expires five years after the date of issuance. The description of the Warrant set forth in this report is qualified in its entirety by reference~~our common stock, except to the ~~full text of~~extent that ~~document, which is attached hereto as Exhibit 10.15.~~any fractional share was rounded up to the nearest whole share.
30
~~Table of Contents~~

Corporate Overview

We were incorporated under the name Imagine Media, Ltd. in August 2007 to publish and distribute Image Magazine, a monthly guide and entertainment source for the Denver, Colorado area. We generated only limited revenue and essentially abandoned the business plan in January 2009.
On September 19, 2011, we, Imagine Media, Ltd., a Delaware corporation, acquired approximately 52% of the outstanding shares of TransBiotec, Inc. ~~(the “Company” or “TBT”~~(“TBT”), a California corporation, from TBT’s directors in exchange for ~~373,315~~124,439 shares of our common stock.
On In January ~~17,~~ 2012, our Board of Directors amended our Certificate of Incorporation changing our name from Imagine Media, Ltd. to TransBiotec, Inc.
~~On January 31, 2012,~~, and we acquired approximately 45% of the remaining outstanding shares of TBT in exchange for ~~329,936~~109,979 shares of our common stock.
With the acquisitions in September 2011 and January 2012 of TBT common stock, we own approximately 99% of the outstanding shares of TBT.
As a result of the acquisitions, TBT’s business is our business, and, unless otherwise indicated, any references to “we” or “us” include the business and operations of TBT.

On March 9, 2020, in connection with our transaction with IDTEC, LLC ~~(as detailed herein)~~ our Board of Directors approved the amendment to our Certificate of Incorporation on March 9, 2020 and stockholders holding 52.24% of our then outstanding voting stock approved ~~the~~an amendment to our Articles of Incorporation. The Certificate of Amendment to our Certificate of Incorporation was for the purpose of, among other things, (i) changing our name from “TransBiotec, Inc.” to “SOBR Safe, Inc.”, (ii) effecting a 1-for-33.26 reverse stock split of our common stock, and (iii) decreasing our authorized common stock from 800,000,000 shares to 100,000,000 ~~shares, and~~shares. The Certificate of Amendment to our Certificate of Incorporation became effective with the State of Delaware on April 24, 2020.

As a result of the reverse stock split effected by our Certificate of Amendment to our Certificate of Incorporation, every 33.26 shares of our outstanding common stock prior to the effect of that amendment were combined and reclassified into one share of our common ~~stock, and the number of outstanding shares of our common stock at the time was reduced from 266,097,657 (pre-split) to approximately 8,000,000 (post-split).~~stock. No fractional shares were issued in connection with the reverse stock split, and any of our stockholders that would have been entitled to receive a fractional share as a result of the reverse stock split ~~will instead receive~~received one additional share of our common stock in lieu of the fractional share. The reverse stock split ~~will~~did not in itself affect any stockholder’s ownership percentage of our common stock, except to the extent that any fractional share iswas rounded up to the nearest whole share.

At the open of ~~trading~~market on ~~June 8, 2020,~~April 28, 2022, our ~~new name and~~1-for-3 reverse ~~stock~~ split ~~went effective with OTC Markets, and we began trading on the “OTC Pink Current Information” tier of OTC Markets on a post reverse stock split basis. Our ticker symbol for the quotation~~ of our common stock ~~is now “SOBR”. On November~~went effective with FINRA and OTC Markets. As a result, all common stock share amounts, as well as share amounts and exercise and conversion prices in derivative security instruments have been adjusted to reflect the reverse stock split.
30
Table of Contents
Pursuant to approval of an application with Nasdaq to uplist our common stock to their exchange under the ticker symbol “SOBR,” our common stock began trading and quoted on Nasdaq Capital Market on May 16, ~~2020, we began trading~~2022. Prior to this uplist to Nasdaq Capital Market, our common stock was quoted on the “OTCQB” tier of the OTC ~~Markets.~~Markets under the ticker symbol “SOBR.”

Our corporate offices are located at ~~885 Arapahoe Avenue, Boulder, CO 80302,~~6400 South Fiddlers Green Circle, Suite 525, Greenwood Village, Colorado 80111, telephone number (844) 762-7723.

The following discussion:

o
summarizes our plan of operation; and

o
analyzes our financial condition and the results of our operations for the ~~three and nine months~~three-months ended ~~September 30, 2021.~~March 31, 2022.

This discussion and analysis should be read in conjunction with our financial statements included as part of this Quarterly Report on Form 10-Q, as well as our financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.
Business Operations and Outlook
We develop and provide companies with non-invasive technology to quickly and safely identify potential alcohol issues with their employees or contractors, that if left undetected could cause injury or death. These technologies are integrated within our robust and scalable data platform, producing statistical and measurable user and business data. Our mission is to save lives, increase productivity, create significant economic benefit for our customers and positively impact behavior. To that end, we developed the scalable, patent-pending SOBRSafe™ hardware/software platform for non-invasive alcohol detection and identity verification, a solution that has anticipated applications in commercial vehicle fleets, manufacturing and warehousing, construction, DUI probation, third-party alcohol testing, outpatient alcohol rehabilitation and youth drivers. We believe that uniform daily use of our device could result in insurance savings across workers’ compensation, general liability, umbrella and fleet policies.
We have successfully completed several pilot testing programs involving our SOBRcheck™ device, which is our first device that has our scalable, patent-pending SOBRSafe™ software platform for non-invasive alcohol detection and identity verification. These pilot programs have provided validation of both our SOBRSafe™ software platform and our SOBRcheck™ device. In addition, during the pilot testing of our SOBRcheck™ device we discovered that alcohol-based hand sanitizer caused false readings by the device. In response to this discovery, we have made adjustments to the analytics in our SOBRSafe™ technology and added a required protocol of not utilizing alcohol-based sanitizers to our protocols for using the SOBRcheck™ device.
As a result, we have now progressed to commercial production, launch and sale of our first SOBRcheck™ devices and software solution to initial customers with an initial focus on last mile delivery fleets. At the end of 2021, we had several customers in the sales cycle, but our SOBRcheck™ devices were not delivered to them until January 2022. Since, we have executed customer agreements, invoiced these customers and are in revenue as of first quarter 2022.
Our second device, a wearable wristband (SOBRsure™), utilizes the same SOBRSafe™ sensor technology and software platform, which was validated during the SOBRcheck™ pilot tests. The primary intended application for this band is for young individual drivers and commercial fleet management, with an additional potential application in managed care/alcohol rehabilitation. We plan for the wearable band to be commercially available in August 2022.
Design, manufacturing and assembly of our SOBRcheck™ and SOBRsure™ devices will take place in the United States. We currently utilize two companies for manufacturing of the SOBRcheck™ device. We do not have agreements in place with these companies and we operate with them on a purchase order/payment basis. We supply a purchase order, which they fulfill, and then they send us an invoice.

31
Table of Contents
Our SOBRsafe™ technology can also be deployed across numerous additional devices for various uses; among those we are currently exploring include possible integrations with existing telematics systems, and it could be licensed by non-competitive third parties.
On January 15, 2021, we initiated a Private Offering (the “Offering”) of up to 40 Units ($2,000,000) with each Unit consisting of one $50,000 principal amount secured convertible debenture, convertible at $9 per share, and a Warrant to purchase 8,333 shares of the Company’s common stock at $9 per share. The Secured Debentures carry interest at 12% and mature 24 months after issuance. The Warrants are exercisable six months after issuance and expire 24 months after issuance. The Offering closed on May 31, 2021 and raised $2,005,000.
On September 28, 2021, we completed a financing transaction of a convertible debenture and issued warrants (the “Debenture”) that raised $2,225,000 of net proceeds after debt issuance costs. The Debenture is for a face amount $3,048,781 with an Original Issue Discount of 18% and was due March 27, 2022, if not converted. The Debenture matured on March 27, 2022 and we did not make the required principal payment putting the Company in default under the terms of the Debenture. On March 30, 2022, we entered into a Waiver Agreement with the purchaser, under which the Purchaser granted the Company a waiver of the default penalties under the Debenture such that any default penalties will not be charged and/or due until April 17, 2022 (the “Waiver”). In exchange for the Waiver of the default penalties the Company agreed to: (i) amend the original Common Stock Warrant (the “Original Warrant”) issued by the Company to the purchaser dated September 27, 2021 to extend the Termination Date (as defined in the Original Warrant) from September 28, 2026 to September 28, 2028; and (ii) issue the Purchaser a second Common Stock Purchase Warrant (the “New Warrant”) entitling the Purchaser to subscribe for and purchase up to an additional 101,626 shares of our common stock, expiring March 29, 2029, with all other terms of the warrant the same as the Original Warrant. The extended terms of the Original Warrants and the issuance of the New Warrants resulted in additional fair value of $164,000 and $700,000, respectively during the three-month period ended March 31, 2022. As a result of the change in the Original Warrant extended termination date and the New Warrant issued in exchange for the Waiver, the Company evaluated the reacquisition price of the Debenture under ASC 470-50-40-2 to be $3,912,781. As the net carrying amount of the Debenture is $3,048,781, a loss on extinguishment of debt of $864,000 was recognized during the three-month period ended March 31, 2022. We did not cure the default as of the Waiver date resulting in mandatory penalties of $914,634 accrued as of March 31, 2022.
We deployed the net funding we received from the 2021 financing ($4.2M) to bolster and expedite product development (SOBRcheck™ and SOBRsure™), deploy sales and marketing initiatives to develop the SOBR brand and grow the business and expand the employee base in correlation with customer and technology development.
On May 18, 2022, we received approximately $8,799,000 of net proceeds from the sale of an underwritten public offering of 2,352,942 units (Units) at a public offering price of $4.25 per Unit, with each Unit consisting of one share of our Common Stock, par value $0.00001, and two warrants each to purchase one share of Common Stock. The Warrants included in the Units are exercisable immediately and have an exercise price of $4.25 per share (100% of the price per Unit sold in the offering). The Warrants will not be listed for trading and will expire five years from the date of their issuance. On May 19, 2022, the $3,048,781 principal balance of the Armistice Capital Master Fund, Ltd 18% Original Issue Discount Convertible Debenture in default at March 31, 2022, was paid in full satisfying all amounts due and accrued under the default, including penalty, damages and interest provisions of the loan agreement.
Management believes that the net offering proceeds of approximately $5,729,000, after the payment of the defaulted loan balance of $3,048,781, provides adequate working capital for operating activities for the next twelve months after the date the financial statements are issued. However, convertible notes payable plus interest at 12% per annum are due 24 months from issuance. Total principal balances of the convertible notes at March 31, 2022 are $2,005,000 and are due $1,100,000, $155,000 and $750,000 in March 2023, April 2023 and May 2023, respectively. The notes are convertible at $9 per share of the Company’s common stock. The notes contain both voluntary and automatic conversion features. The notes may be convertible at any time, by the holders, beginning on the date of issuance. The notes automatically convert into shares of the Company’s common stock if the Company’s common stock closes at or above $6 per share for five (5) consecutive trading days while listed on Nasdaq. Should the notes not automatically convert or a significant portion of the note holders voluntarily not convert the notes to our common stock, we may need additional funds beyond the money raised in the underwritten public offering.
In addition capital may be required under the following circumstances, 1) accelerated customer acquisition increasing capital outlay, 2) advanced purchasing of materials due to COVID backlog, 3) acquisition of new technology, 4) potential acquisition of a key asset, and 5) global expansion.
32
Table of Contents

Results of Operations for Three Months Ended ~~September 30, 2021~~March 31, 2022 Compared to Three Months Ended ~~September 30, 2020~~March 31, 2021

Summary of Results of Operations

Three Months Ended
September 30,

Three Months Ended
March 31,

2021

2020

2022

2021

Revenue

$ -

$ -

$ 1,500

$ -

Cost of goods sold

1,100

-

Gross Profit

400

-

Operating expenses:

General and administrative

316,329

191,589

2,269,175

776,861

Stock-based compensation expense

147,163

-

442,784

18,690

Management salaries and consulting fees

632,964

352,266

Research and development

566,655

152,123

47,459

171,463

Asset impairment adjustment

-

-

Total operating expenses

1,663,111

695,978

2,759,418

967,014

Operating loss

(1,663,111 )

(695,978 )

(2,759,018 )

(916,014 )

Other income (expense):

Loss on extinguishment of debt, net

-

-

Gain on fair value adjustment – derivatives

-

-

Other income (expense), net

27

-

Loss on extinguishment of debt

(864,000 )

-

Loss on fair value adjustment – derivatives

(340,000 )

-

Interest expense

(227,475 )

(41,622 )

(1,026,471 )

(25,878 )
Amortization of interest – conversion features

(130,830 )

-

(580,221 )

(9,542 )
Total other expense, net

(358,305 )

(41,622 )

(2,810,665 )

(35,420 )

Net loss

$ (2,021,416 )

$ (737,600 )

$ (5,569,683 )

$ (1,002,434 )

Operating Loss; Net Loss

Our net loss increased by ~~$1,283,816~~$4,567,249 from ~~$737,600~~$1,002,434 to ~~$2,021,416,~~$5,569,683, from the three-month period ended ~~September 30, 2020~~March 31, 2021 compared to the three-month period ended ~~September 30, 2021. Our operating loss increased by $967,133, from $695,978 to $1,663,111 for the same periods.~~March 31, 2022. The change in our net loss and operating loss for the three months ended ~~September 30, 2021,~~March 31, 2022, compared to the same prior year period, is primarily a result of acceleration of our planned strategic operational and financing activities resulting in increases in ~~our~~interest and other financing related costs, general and administrative ~~expense,~~expenses, and stock-based compensation expense, ~~and~~offset by a reduction in research and development expense. The changes are detailed below.

Revenue

~~We have not had any revenues since our inception. Since September 2011,~~Prior to the three-month period ended March 31, 2022, we ~~have been involved in the development~~progressed to commercial production, launch and sale of our ~~patented SOBR® Safe™ system, including, but not limited~~first SOBRcheck™ devices and software solution to initial customers with our devices being delivered for use in January 2022. We executed customer agreements, invoiced these customers and recognized revenue of $1,500 during the first quarter 2022.
Gross Profit
The cost of goods sold for the three-months ended March 31, 2022 was $1,100 resulting in a gross profit of $400 and a gross margin of 27%. Due to the ~~developing, testing~~limited history of generating revenue, the gross profit and ~~marketing~~gross margin at March 31, 2022 is not indicative of ~~SOBR®Check™,~~ our ~~unique alcohol sensor technology. Although we have not had any sales to date, we are planning to be ready to commercialize the SOBR®Check™ device in the fourth quarter of 2021~~future planned performance, our product lines or ~~first quarter of 2022.~~services.

General and Administrative Expenses

General and administrative expenses increased by ~~$124,740,~~$1,492,314, from ~~$191,589~~$776,861 for the ~~three month~~three-month period ended ~~September 30, 2020~~March 31, 2021 to ~~$316,329~~$2,269,175 for the ~~three month~~three-month period ended ~~September 30, 2021,~~March 31, 2022. The increase from the same prior year period is primarily due to increases in ~~facilities~~our employee compensation and benefits of $128,552, a one-time debt default penalty of $914,634 related to the Armistice Convertible Debt, stock-option expense of $386,057, professional, legal and consulting services of $62,767, and facility rents ~~marketing and promotion, accounting and~~of $12,856, offset by a reduction in other ~~professional fees.~~general & administrative expenses in aggregate of $12,552.

3233
Table of Contents

Stock-Based Compensation Expense

We had stock-based compensation expense of ~~$147,163~~$442,784 for the ~~three months~~three-months ended ~~September 30, 2021,~~March 31, 2022, compared to $0$18,690 for the ~~three months~~three-months ended ~~September 30, 2020.~~March 31, 2021. The stock-based compensation expense ~~in 2021~~ was related to the issuance of our common stock or restricted stock units as compensation to certain consultants and employees.
~~Management Salaries and Consulting Fees~~
Management salaries and consulting fees increased by $280,698, to $632,964 for the three months ended September 30, 2021, compared to $352,266 for the three months ended September 30, 2020. The management salaries and consulting fees in both years were related to salaries, fees and incentive based stock options to our management and consultants.

Research and Development

Research and development ~~increased~~decreased by ~~$403,532,~~$124,004, to ~~$555,655~~$47,459 for the ~~three months~~three-months ended ~~September 30, 2021,~~March 31, 2022, compared to ~~$152,123~~$171,463 for the ~~three months~~three-months ended ~~September 30, 2020.~~March 31, 2021. The ~~increase~~decrease in research and development was due to the ~~ramp up~~finalization of ~~expenses to develop~~our initial development of our SOBR® Safe™ ~~system, including, but not limited to,~~software platform and the ~~developing~~development and ~~testing~~test of ~~SOBRCheck,~~ our ~~unique alcohol sensor technology,~~SOBRcheck™ devices, as we ~~prepare~~prepared to commercialize the device in January 2022.
Fair Value Adjustment – Derivatives
Fair value adjustment – derivatives was a loss of $340,000 for the ~~near future.~~three-month period ended March 31, 2022, which is related to outstanding financial instruments issued in September 2021 that contain an embedded derivative liability component. We did not have any outstanding financial instruments that contain derivative liability components during the three-month period ended, March 31, 2021. The gain or loss related to the instruments are affected by the price of our common stock.

Interest Expense

Interest expense increased by ~~$185,853,~~$1,026,471, from ~~$41,622~~$25,878 for the three-month period ended ~~September 30, 2020~~March 31, 2021 to ~~$227,475~~$1,000,593 for the three-month period ended ~~September 30, 2021. For both periods these amounts are largely due~~March 31, 2022. This increase is primarily attributable to ~~the interest on outstanding debt. The increase between the two periods is largely related to the fact that we had~~us having significantly more outstanding convertible debt during the three months ended ~~September 30, 2021~~March 31, 2022 compared to the same period in ~~2020.~~2021.
The increase of $1,000,593 in interest expense is attributed to the increase in outstanding debt related to interest amortization from original issued debt and convertible warrants in September 2021 of $828,743 and increase in interest amortization of $171,850 from private placement offering in January 2021 of $197,414 for the three-month period ended March 31, 2022, as compared to $25,878 of interest expense for the three-month period ended March 31, 2021.

Amortization of Interest – Conversion Features

During the ~~three months~~three-months ended ~~September 30, 2021,~~March 31, 2022, we had amortization of interest – beneficial conversion ~~features~~feature expense of ~~$130,830~~$580,221 compared to $0$9,542 during the ~~three months~~three-months ended ~~September 30, 2020.~~March 31, 2021, resulting in an increase of $570,679. The expenses for the ~~period in 2021 was related to the amortized discount on convertible notes payable.~~
33
~~Table of Contents~~
~~Results of Operations for Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020~~
~~Summary of Results of Operations~~

Nine Months Ended
September 30,

2021

2020

Revenue

$ -

$ -

Operating expenses:

General and administrative

875,378

400,127

Stock-based compensation expense

334,228

41,302

Management salaries and consulting fees

1,682,557

1,103,828

Research and development

1,052,650

309,403

Asset impairment adjustment

-

25,320,555

Total operating expenses

3,944,813

27,175,215

Operating loss

(3,944,813 )

(27,175,215 )

Other income (expense):

Loss on extinguishment of debt, net

-

(269,144 )
Gain on fair value adjustment – derivatives

-

60,650

Interest expense

(399,381 )

(107,253 )
Amortization of interest – conversion features

(222,373 )

(1,407,675 )
Total other expense, net

(621,754 )

(1,723,422 )

Net loss

$ (4,566,567 )

$ (28,898,637 )
The asset impairment adjustment classified as an operating expense herein was previously reported as other expense, net. As a result, the operating loss previously reported for the nine-month period ended September 30, 2020 was understated by $25,320,555 and total other expenses, net was overstated by the same amount. The error had no effect on the net loss for the nine-month period ended September 30, 2020.
~~Operating Loss; Net Loss~~
Our net loss decreased by $24,332,070 from $28,898,637 to $4,566,567, from the nine-month period ended September 30, 2020 compared to the nine-month period ended September 30, 2021. Our operating loss decreased by $23,230,402, from $27,175,215 to $3,944,813 for the same periods. The change in our net loss and operating loss for the nine months ended September 30, 2021, compared to the prior year period, is primarily a result of an asset impairment expense related to the assets we acquired from IDTEC during the nine months ended September 30, 2020, partially offset by increases in general and administrative expenses, stock-based compensation expense, management salaries and consulting fees, and research in development, all of which are primarily related to our increased operations during the nine months ended September 30, 2021 compared to September 30, 2020. The changes are detailed below.
34
~~Table of Contents~~
~~Revenue~~
We have not had any revenues since our inception. Since September 2011, we have been involved in the development of our patented SOBR® Safe™ system, including, but not limited to, the developing, testing and marketing of SOBR®Check™, our unique alcohol sensor technology. Although we have not had any sales to date, we are planning to be ready to commercialize the SOBR®Check™ device in the fourth quarter of 2021 or first quarter of 2022.
~~General and Administrative Expenses~~
General and administrative expenses increased by $475,251, from $400,127 for the nine-month period ended September 30, 2020 to $875,378 for the nine-month period ended September 30, 2021, primarily due to increases in facilities rents, marketing and promotion, accounting and other professional fees.
~~Stock-Based Compensation Expense~~
We had stock-based compensation expense of $334,228 for the nine months ended September 30, 2021, compared to $41,302 for the nine months ended September 30, 2020. The stock-based compensation expense for both periods was related to the issuance of our common stock as compensation to certain consultants and employees.
~~Management Salaries and Consulting Fees~~
Management salaries and consulting fees increased by $578,729, to $1,682,557 for the nine months ended September 30, 2021, compared to $1,103,828 for the nine months ended September 30, 2020. The management salaries and consulting fees in both years were related to salaries, fees, and incentive based stock options to our management and consultants.
~~Research and Development~~
Research and development increased by $743,247, to $1,052,650 for the nine months ended September 30, 2021, compared to $309,403 for the nine months ended September 30, 2020. The increase in research and development was due to the ramp up of expenses to develop our SOBR® Safe™ system, including, but not limited to, the developing and testing of SOBRCheck, our unique alcohol sensor technology, as we prepare to commercialize the device in the near future.
~~Asset Impairment Adjustment~~
We had an asset impairment adjustment of $25,320,555 in the nine months ended September 30, 2020. We did not have an asset impairment adjustment in the nine months ended September 30, 2021. The asset impairment adjustment in 2020 was related to the value of the stock we issued to IDTEC that was attributed to the robotic assets we acquired from IDTEC versus the value of the assets. When we negotiated the transaction with IDTEC in early-to-mid-2019, the agreed to issue IDTEC 12,000,000 shares of our common stock (post-split) in exchange for the consideration they were transferring to us at the close of the transaction. At the time we negotiated the transaction and signed the Asset Purchase Agreement, our common stock was trading at a lower price than what it was trading at when we closed the transaction and issued the shares. As a result, during the nine months ended September 30, 2020, we impaired the value of the robotic assets we received in the transaction.
35
~~Table of Contents~~
~~Loss on Extinguishment of Debt, Net~~
Loss on extinguishment of debt, net was $0 for the nine months ended September 30, 2021, compared to $269,144 for the nine months ended September 30, 2020. This decrease was due to us converting several notes payable into shares of our common stock during the nine months ended September 30, 2020, but none during the nine months ended September 30, 2021.
~~Gain on Fair Value Adjustment – Derivatives~~
Gain on fair value adjustment – derivatives was $0 for the nine months ended September 30, 2021, compared to $60,650 for the nine months ended September 30, 2020. For the period in 2020 the amount is related to us having an outstanding financial instrument that contained an embedded derivative liability. The gain related to the instrument is tied to the price of our common stock.
~~Interest Expense~~
Interest expense increased by $292,128, from $107,253 for the nine-month period ended September 30, 2020 to $399,381 for the nine-month period ended September 30, 2021. For both periods these amounts are largely due to the interest on outstanding debt. The increase between the two periods is largely related to the fact that we had significantly more outstanding debt during the nine months ended September 30, 2021 compared to the same period in 2020.
~~Amortization of Interest – Conversion Features~~
During the nine months ended September 30, 2021, we had amortization of interest – conversion features expense of $222,373 compared to $1,407,675 during the nine months ended September 30, 2020. The expenses for both periods were related to the amortized discount on convertible notes ~~payable.~~payable of which we had substantially more outstanding convertible debt during the three months ended March 31, 2022 compared to the same period in 2021.

3634
Table of Contents

Liquidity and Capital Resources for ~~Nine~~Three Months Ended ~~September 30, 2021~~March 31, 2022 Compared to ~~Nine Months Ended September 30, 2020~~December 31, 2021

Introduction

During the ~~nine months~~three-months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of ~~September 30, 2021~~March 31, 2022 is ~~$2,185,233~~$107,448 and our current normalized monthly operating cash flow burn rate is approximately $200,000. As a result, we ~~do not have short term cash needs, but~~ need to raise additional funds to finance our ~~long term~~current and long-term business plans. ~~Our cash needs are being satisfied through proceeds from the sales of our securities and loans from both related parties and third parties.~~ We currently do not believe we will be able to satisfy our cash needs from our revenues for some time, and there is no guarantee we will be successful in the future ~~satisfying~~to adequately satisfy these needs through the proceeds generated from the sales of our ~~securities.~~securities or additional financing

Our cash, current assets, total assets, current liabilities, and total liabilities as of ~~September 30, 2021~~March 31, 2022 and as of December 31, ~~2020,~~2021, respectively, are as follows:

September 30,
2021

December 31,
2020

Change

March 31,
2022

December 31, 2021

Change

Cash

$ 2,185,233

$ 232,842

$ 1,952,391

$ 107,448

$ 882,268

$ (774,820 )
Total Current Assets

$ 2,210,132

$ 348,072

$ 1,862,060

242,184

934,282

(692,098 )
Total Assets

$ 5,566,681

$ 3,986,573

$ 1,580,108

3,420,751

4,209,215

(788,464 )
Total Current Liabilities

$ 2,998,714

$ 922,089

$ 2,076,625

7,247,302

3,981,935

3,265,367

Total Liabilities

$ 3,457,289

$ 947,089

$ 2,510,200

7,628,302

4,652,808

2,975,494

Our current assets and total assets ~~increased~~decreased as of ~~September 30, 2021,~~March 31, 2022, as compared to December 31, ~~2020,~~2021, primarily due to ~~us having more~~the use cash ~~on hand at September 30, 2021, as a result of debt issued during the nine months ended September 30, 2021.~~to support our negative cash flow from operations.

Our current liabilities increased as of ~~September 30, 2021,~~March 31, 2022, as compared to December 31, ~~2020.~~2021. This increase was primarily due to increases in accounts payable, accrued interest payable, accrued expenses payable, derivative liability, ~~and~~ convertible debenture payable ~~partially offset by decreases in accrued expenses,~~ and ~~common stock subscriptions payable.~~current maturities of long-term debt.

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Sources and Uses of Cash

Operations

We had net cash used in operating activities of ~~$2,277,609~~$774,820 for the ~~nine-month~~three-month period ended ~~September 30, 2021,~~March 31, 2022, as compared to net cash used for operating activities of ~~$1,443,783~~$668,781 for the ~~nine-month~~three-month period ended ~~September 30, 2020.~~ March 31, 2021. For the period in 2022, the net cash used in operating activities consisted primarily of our net loss of $5,569,683, offset by non-cash expense items including depreciation and amortization of $96,366, loss on extinguishment of debt of $864,000, change in fair value of a derivative liability by $340,000, amortization of interest – conversion features of $580,221, amortization of interest of $423,782, stock options expense of $491,441, and stock-based compensation expense of $442,784, and changes in our assets and liabilities for accounts receivable of ($500), inventory of ($65,489), prepaid expenses of ($16,733), accounts payable of $96,886, accrued expenses of $931,796, and accrued interest payable of $57,696, and related party payables of $12,437.
For the period in 2021, the net cash used in operating activities consisted primarily of our net loss of ~~$4,566,567,~~$1,002,434, offset by depreciation and amortization of ~~$289,098,~~$96,366, amortization of interest – beneficial conversion ~~features~~feature of ~~$222,373, amortization~~$9,562, stock warrants expense of ~~interest of $275,052,~~$13,472, stock options expense of ~~$399,259, and~~$105,013, stock-based compensation expense of ~~$334,228,~~$18,690, and changes in our assets and liabilities of amounts due from related parties of ($2,792), prepaid expenses of ~~$(19,361), other assets of ($7,146),~~$5,559, accounts payable of ~~$604,834,~~$65,317, accrued expenses of ($~~6,961)~~30,566), accrued interest payable of ~~$58,733,~~($42,950), related party payables of ~~$780,~~$7,533, and common stock subscriptions payable of $138,069. For the period in 2020, the net cash used in operating activities consisted primarily of our net loss of $28,898,637 and change in fair value of derivative liability of $60,650, offset by a loss on debt extinguishment, net of $269,144, depreciation and amortization of $133,571, amortization of interest – beneficial conversion feature of $1,407,675, stock warrants expense of $8,856, stock options expense of $343,549, stock-based compensation expense of $41,302, and asset impairment adjustment of $25,320,555, and changes in our assets and liabilities of prepaid expenses of $994, other assets of ($8,680), accounts payable of $140,906, accrued expenses of ($83,495), accrued interest payable of ($6,697), and related party payables of ($51,976).$88,469.

3735
Table of Contents

Investments

We had no cash provided by or used for investing activities during the ~~nine-month~~three-month period ended ~~September 30, 2021~~March 31, 2022 or ~~September 30, 2020.~~March 31, 2021.

Financing

~~Our net~~We had no cash ~~provided~~provide by or used in financing activities ~~for~~during the ~~nine-month~~three-month period ended ~~September 30, 2021 was $4,230,000, compared to $1,741,665 for~~March 31, 2022. For the ~~nine-month~~three-month period ended ~~September 30, 2020. For the nine-month period ended September 30,~~March 31, 2021, our net cash from financing activities consisted of proceeds from notes payable – non-related parties of ~~$1,005,000,~~$600,000 and proceeds from notes payable – related parties of ~~$1,030,000, repayments~~$530,000.
Contractual Obligations and Commitments
At March 31, 2022, the Company had no debt obligations and short term leases and was not committed to material contractual obligations for the design, production, delivery or assemble of ~~notes payable-related parties~~its software platform or associated devices.
Off Balance Sheet Arrangements
We have no off-balance sheet arrangements as of ~~($30,000), proceeds from convertible debenture payable~~March 31, 2022 and December 31, 2021.
Effects of $2,500,000 and debt issuance costs of ($275,000). For the nine-month period ended September 30, 2020, our net cash from financing activities consisted of proceeds from offering of preferred stock – related parties of $1,700,000, and proceeds from notes payable – non-related parties of $41,665.
COVID 19
On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak and its variants continues to evolve as of the date of this filing. Management is actively monitoring the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak, its variants, and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for fiscal year ~~2021.~~2022. However, if the pandemic continues, it could have an adverse effect on our results of future operations, financial position, and liquidity in ~~year 2021.~~2022.

~~Off Balance Sheet Arrangements~~Effects of Inflation

We do not believe that inflation has had a material impact on our business, revenue or operating results during the periods presented. However, continued increases in inflation could have an adverse effect on our results of future operations, financial position, and liquidity in 2022
Recent Accounting Pronouncements
There have been no ~~off balance sheet arrangements as~~recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2022, or subsequently thereto, that we believe are of ~~September 30, 2021 and December 31, 2020.~~potential significance to our financial statements.
36
Table of Contents

ITEM 3 Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.
38
~~Table of Contents~~

ITEM 4 Controls and Procedures

(a) Evaluation of Disclosure and Controls Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.

As of ~~September 30, 2021,~~March 31, 2022, we carried out an evaluation, under the supervision and with the participation of management, including our ~~chief executive officer~~Chief Executive Officer (our Principal Executive Officer) and ~~chief financial officer~~Chief Financial Officer (our Principal Financial Officer), of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. WeDuring the three-month period ended March 31, 2022, we hired a Chief Financial Officer, whereas previously our Chief Executive Officer also ~~do not have an audit committee. Based~~served as our Principal Financial Officer, and hired a Vice President of Finance and Accounting to improve disclosure controls and procedures, and support additional segregation of financial and internal controls. Also, our Board approved our Audit Committee Charter in compliance with Nasdaq requirements. Although we began mitigating certain limitations in the effectiveness of its system of controls and procedures during the three month period ended March 31, 2022, based on the evaluation described above, and as a result, in part, of ~~not having an audit committee and having one individual serve as our chief executive officer and another individual serve as our chief financial officer,~~the timing of beginning to implement the mitigating improvements, management has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective ~~to the same extent~~and have not significantly improved as reported in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

As funds become available to us, we expect to implement additional measures to improve disclosure controls and procedures.

(b) Changes in Internal Controls over Financial Reporting

~~There was no change~~As noted above, during the three-month period ended March 31, 2022, we hired a Chief Financial Officer, whereas previously our Chief Executive Officer also served as our Principal Financial Officer, and hired a Vice President of Finance and Accounting to improve disclosure controls and procedures, and support additional segregation of financial and internal controls. Also, our Board approved our Audit Committee Charter in compliance with Nasdaq requirements. As a result, we began mitigating certain limitations in the effectiveness of its system of controls and procedures during the three month period ended March 31, 2022, however, due to the timing of beginning to implement these improvements, we do not believe they materially impacted our internal controls over financial reporting ~~that occurred~~or our internal controls over financial reporting during the period covered by this ~~report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.~~report.

(c) Officer’s Certifications

Appearing as an exhibit to this quarterly report on Form 10-Q are “Certifications” of our Chief Executive and Financial Officer. The Certifications are required pursuant to Sections 302 of the Sarbanes-Oxley Act of 2002 (the “Section 302 Certifications”). This section of the quarterly report on Form 10-Q contains information concerning the Controls Evaluation referred to in the Section 302 Certifications. This information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

3937
Table of Contents

PART II – OTHER INFORMATION
ITEM 1 Legal Proceedings

On December 6, 2006, Orange County Valet and Security Patrol, Inc. filed a lawsuit against us in Orange County California State Superior Court for Breach of Contract in the amount of $11,164. A default judgment was taken against us in this matter. In mid-2013 we learned the Plaintiff’s perfected the judgment against us, but we have not heard from the Plaintiffs as of ~~November 2021.~~May 2022. In the event we pay any money related to this lawsuit, IDTEC, LLC agreed, in connection with us closing the asset purchase transaction with IDTEC, to pay the amount for us in exchange for shares of our common stock.
We had one outstanding judgment against us involving a past employee of the Company. The matter was under the purview of the State of California, Franchise Tax Board, Industrial Health and Safety Collections. We owed approximately $28,786 plus accrued interest of approximately $53,000 to our ex-employee for unpaid wages under these Orders. On March 8, 2021, we received an Acknowledgement of Satisfaction of Judgement-Full by the California Court notifying us that the judgement has been settled with a payment of approximately $85,000 including the accrued interest owed through settlement date and legal fees of approximately $3,000. IDTEC, LLC agreed, in connection with us closing the asset purchase transaction with IDTEC, to pay the amount for us in exchange for shares of our common stock acquired through the exercise of a warrant held by IDTEC, LLC.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

ITEM 1A Risk Factors

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended ~~September 30, 2021~~March 31, 2022 we issued the following unregistered securities:

On ~~September 28, 2021,~~January 12, 2022, we ~~closed a financing transaction with a leading healthcare fund (the “Purchaser”). Under the terms of the financing, we received $2,500,000 from the Purchaser and in exchange~~ issued ~~the Purchaser an 18% Original Issue Discount Convertible Debenture in the principal amount of $3,048,780.50 (the “Debenture”) and a Common Stock Purchase Warrant to purchase up to 1,219,512~~16,667 shares of our common stock ~~(the “Warrant”). Additional terms~~for restricted stock units that vested during 2021. This issuance was made in reliance on Section 4(a)(2) of the ~~Debenture~~Securities Act of 1933, as amended. To make this determination we relied on our knowledge of the purchaser and ~~Warrant~~the representations of the purchaser contained in certain agreements, which indicated the purchaser was knowledgeable about our management and our operations, was a sophisticated investor, and understood the purchase was part of a private placement.
On March 1, 2022, we entered in to Share Exchange Agreements with David Gandini, one of our officers and directors, and Gary Graham, our largest shareholder, to exchange 333,334 and 666,667 shares of our common stock into 1,000,000 shares and 2,000,000 shares of our Series B Preferred Stock, respectively. These stock exchanges of common stock for preferred stock were done as conditions of our planned underwritten offering and planned listing on Nasdaq. The shares of our Series B Convertible Preferred Stock have liquidation preference over our common stock, receive dividends in pari passu with our common stockholders, are ~~set forth under Part II Item 5, herein.~~convertible into shares of our common stock on a 1-for-1 basis, and vote on an “as converted” basis. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The ~~investor is accredited,~~investors are sophisticated, familiar with our operations, and there was no general solicitation or advertising.

40
On March 3, 2022, we issued 7,917 shares of common stock under the terms of a $47,500 convertible note payable issued March 6, 2020 with interest at 5%, due March 6, 2022 and convertible at $6 per share. This issuance was made in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended. To make this determination we relied on our knowledge of the purchaser and the representations of the purchaser contained in certain agreements, which indicated the purchaser was knowledgeable about our management and our operations, was a sophisticated investor, and understood the purchase was part of a private placement.
~~Table of Contents~~

ITEM 3 Defaults Upon Senior Securities

On December 28, 2010, we borrowed $11,810 from a related party. The note payable carries an interest rate of 0% and matured on December 31, 2012. As of ~~September 30, 2021~~March 31, 2022 this note was in default.

On February 20, 2012, we borrowed $3,750 from a non-related party. The note payable carries an interest rate of 12% and matured on February 19, 2013. As of ~~September 30, 2021~~March 31, 2022 this note was in default.

On March 20, 2012, we borrowed $5,433 from a non-related party. The note payable carries an interest rate of 12% and matured on March 19, 2013. As of ~~September 30, 2021~~March 31, 2022 this note was in default.

On September 27, 2013, we borrowed $15,000 from a non-related party. The note payable carries an interest rate of 9% and matured on December 25, 2013. As of ~~September 30, 2021~~March 31, 2022 this note was in default.

On March 14, 2014, we borrowed $5,000 from a non-related party. The note payable carries an interest rate of 10% and matured on September 14, 2014. As of ~~September 30, 2021~~March 31, 2022 this note was in default.
38
Table of Contents

On July 31, 2015, we borrowed $2,500 from a non-related party. The note payable carries an interest rate of 10% and matured on November 28, 2015. As of ~~September 30, 2021~~March 31, 2022 this note was in default.
On September 28, 2021, we received from a non-related party $2,500,000 for an 18% Original Issue Discount Convertible Debenture in the principal amount of $3,048,781. As of March 31, 2022 this note was in default. On May 19, 2022 the principal balance was paid in full satisfying all amounts due and accrued under the default and damages provisions of the loan agreement.

ITEM 4 Mine Safety Disclosures

There have been no events which are required to be reported under this Item.

ITEM 5 Other Information

~~Financing Transaction~~On May 13, 2022, we entered into an underwriting agreement (the “Underwriting Agreement”), with Aegis Capital Corp., who acted as the lead book running manager (the “Underwriter”), pursuant to which we agreed to sell to the Underwriter in a firm commitment underwritten public offering (the “Offering”) an aggregate of 2,352,942 units. Each unit consisted of one share of our common stock, par value $0.00001 per share (the “Common Stock”), and two warrants (“Warrants”, and together with the Common Stock the “Units”), at a public offering price of $4.25 per Unit. Each Warrant included in the Units is exercisable for one share of Common Stock, is exercisable immediately, has an exercise price of $4.25 per share, which represents 100% of the price per unit sold in the Offering, and expires five years from the date of issuance. The exercise price of the Warrant may adjust downward based on certain events. The Common Stock began trading on the Nasdaq Capital Market under the symbol SOBR on May 16, 2022. The Warrants are non-tradeable.

~~On September 28, 2021, we closed~~The Units were offered and sold to the public pursuant to the Company’s registration statement on Form S-1 (File No. 333-262665), initially filed by us with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) on February 11, 2022, and declared effective on May 13, 2022.
In addition, the Underwriter was granted a ~~financing transaction with a leading healthcare fund (the “Purchaser”). Under~~45-day option, exercisable in one or more times in whole or in part, to purchase up to an additional 352,941 shares of Common Stock and/or up to an additional 705,882 Warrants solely to cover over-allotments. The over-allotment shares of Common Stock can be purchased at the public offering price of the Units ($4.25), less the underwriting discounts payable by us, and the Warrants can be purchased for $0.01 per Warrant.
The Underwriting Agreement contains customary representations, warranties and agreements by us, customary conditions to closing, indemnification obligations of us and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. Further, pursuant to the terms of the ~~financing,~~Underwriting Agreement and related “lock-up” agreements, we, ~~received $2,500,000 from~~each director and executive officer of our, and certain stockholders have agreed with the ~~Purchaser and in exchange~~Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of Common Stock or securities convertible into Common Stock for a period of 180 days (24 months for the Company) commencing on the May 13, 2022, the date of the final prospectus.
On May 17, 2022, we entered into a warrant agent agreement (the “Warrant Agent Agreement”) with Equiniti Trust Company (“Warrant Agent”), to serve as our warrant agent for the Warrants. Upon the closing of the Offering, the Warrant Agent issued the ~~Purchaser an 18% Original Issue Discount Convertible Debenture in~~Warrants.
On May 18, 2022, pursuant to the ~~principal amount of $3,048,780.50 (the “Debenture”) and a Common Stock Purchase Warrant~~Underwriting Agreement, we issued Representative’s Warrants to purchase up to ~~1,219,512~~an aggregate of 141,177 shares of ~~our common stock~~Common Stock (the ~~“Warrant”~~“Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on November 17, 2022, until May 17, 2027. The initial exercise price of Representative's Warrants is $5.3125 per share, which equals 125% of the public offering price per Unit in the Offering.

The ~~Debenture is convertible: (a) voluntarily by the Purchaser at any time into shares of our common stock at the lesser of (i) 100% of the closing price our common stock~~Offering closed on the trading day immediate prior to the Closing Date under the Debenture, or (ii) 75% of the average VWAP of our common stock (representing a 25% discount) during the 5 trading day period immediately prior to the applicable conversion date (on an as adjusted basis giving effect to any splits, dividend and the like during such 5 Trading Day period) (the “Conversion Price”), or (b) automatically upon the occurrence of a Qualified Offering (as defined in the Debenture) into shares of our common stock at the lesser of: (i) the Conversion Price or (ii) 75% of the offering price of the securities offered in the Qualified Offering. May 18, 2022.
The ~~Debenture matures on March 27, 2022, does not accrue interest unless there is an event of default under the terms of the Debenture, and contains industry standard default and other provisions. The~~foregoing description of the ~~Debenture set forth in this report is qualified in its entirety by reference to the full text of that document, which incorporated herein as Exhibit 10.17.~~
~~The~~Underwriting Agreement, Representative’s Warrants and Warrant is exercisable at any time in the next five (5) years into shares of our common at an exercise price of $2.00 per share, unless an event of default occurs, at which time the exercise price will adjust to $1.00 per share. The Warrant contains a cashless exercise provision but only in the event we fail to have an effective registration statement registering the shares underlying the Warrant at any time beginning six (6) months from the date of the Warrant. The description of the Warrant set forth in this report is qualified in its entirety by reference to the full text of that document, which is incorporated herein as Exhibit 10.18.
~~In connection with the financing transaction we entered into a Securities Purchase~~Agent Agreement are not complete and ~~Registration Rights Agreement with the Purchaser, both with standard industry terms. The descriptions of the Securities Purchase Agreement and Registration Rights Agreement set forth in this report~~ are qualified in their entirety by ~~reference~~references to the full text of ~~those documents,~~the Underwriting Agreement, the form of Representative’s Warrants, the Warrant Agent Agreement and the Form of Unit Warrant, which are filed as exhibits 1.1, 4.1, 4.2 and 4.3, respectively, to this report and are incorporated ~~herein as Exhibit 10.19 and Exhibit 10.20, respectively.~~by reference herein.

4139
Table of Contents

ITEM 6 Exhibits

Item No.
Description

~~Description~~
1.1 (19)
Underwriting Agreement by and between SOBR Safe, Inc. and Aegis Capital Corp. dated May, 2022

3.1 (1)

Articles of Incorporation of Imagine Media, Ltd.

3.2 (2)

Articles of Amendment to Articles of Incorporation to TransBiotec, Inc.

3.3 (3)

Certificate of Amendment to Certificate of Incorporation filed with the State of Delaware on May 25, 2017

3.4 (6)

Amended and Restated Bylaws of SOBR Safe, Inc.

3.5 (10)

Certificate of Amendment to Certificate of Incorporation of TransBiotec, Inc. changing name to SOBR Safe, Inc., effecting 1-for-33.26 reverse stock split and decreasing authorized common stock to 100M shares
4.1 (19)
Form of Representative’s Warrant
4.2 (19)
Warrant Agency Agreement
4.3 (19)
Form of Unit Warrant

10.1 (4)

Asset Purchase Agreement dated May 6, 2019 between IDTEC, LLC and TransBiotec, Inc.

10.2 (5)

Common Stock Purchase Agreement with Charles Bennington dated August 23, 2019

10.3 (5)

Share Exchange Agreement with Michael Lanphere dated August 23, 2019

10.4 (5)

Share Exchange Agreement with Vernon Justus dated August 23, 2019

10.5 (5)

Debt Conversion and Common Stock Purchase Agreement with Michael Lanphere dated August 23, 2019

10.6 (5)

Debt Conversion and Common Stock Purchase Agreement with Devadatt Mishal dated August 23, 2019

10.7 (6)

TransBiotec, Inc. 2019 Equity Incentive Plan

10.8 (6)

Employment Agreement with Kevin Moore dated October 25, 2019

10.9 (8)

Amended Employment Agreement with Kevin Moore dated November 26, 2019

10.10 (6)

Employment Agreement with David Gandini dated October 25, 2019

10.11 (7)

Series A-1 Preferred Stock Purchase Agreement by and between TransBiotec, Inc. and SOBR SAFE, LLC dated December 12, 2019 (with Series A-1 Preferred Stock Certificate of Designation attached)

4240
Table of Contents

10.12 (9)

Amendment No. 1 to Asset Purchase Agreement dated March 23, 2020 by and between IDTEC, LLC and TransBiotec, Inc.

10.13 (10)

Form of Convertible Promissory Note Issued to IDTEC, LLC at Close of Asset Purchase Transaction

10.14 (10)

Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement dated June 5, 2020 by and between IDTEC, LLC and TransBiotec, Inc.

10.15 (10)

Warrant to Purchase Common Stock dated June 5, 2020 issued to IDTEC, LLC

10.16 (11)

Advisory Agreement with Steven Beabout dated October 9, 2020

10.17 (12)

18% Original Issue Discount Convertible Debenture issued by SOBR Safe, Inc. to ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.18 (12)

Warrant to Purchase Common Stock issued by SOBR Safe, Inc. to ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.19 (12)

Securities Purchase Agreement by and between SOBR Safe, Inc. and ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.20 (12)

Registration Rights Agreement by and between SOBR Safe, Inc. and ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021
10.21 (13)
“Form of” Secured Convertible Debenture issued by SOBR Safe, Inc. in $2M Regulation D Offering
10.22 (13)
“Form of” Warrant issued by SOBR Safe, Inc. in Regulation D Offering
10.23 (14)
Transition Agreement by and between SOBR Safe, Inc. and Kevin Moore dated October 30, 2021
10.24(15)
Executive Employment Agreement with Scott Bennett dated August 17, 2021
10.25(15)
Executive Employment Agreement with Michael Watson dated October 11, 2021
10.27 (16)
Executive Employment Agreement with Gerard Wenzel dated January 1, 2022
10.28 (17)
Form of Share Exchange Agreement with David Gandini and Gary Graham for Series B Preferred Stock
10.29 (18)
Waiver by and between SOBR Safe, Inc. and Armistice Capital Master Fund Ltd. dated March 30, 2022

31.1*

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer (filed herewith)

31.2*

Rule 13a-14(a)/15d-14(a) Certification of Chief Accounting Officer (filed herewith)

32.1*

Section 1350 Certification of Chief Executive Officer (filed herewith).
41
Table of Contents

32.2*

Section 1350 Certification of Chief Accounting Officer (filed herewith).

101.INS **

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

101.SCH **

Inline XBRL Taxonomy Extension Schema Document

101.CAL **

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF **

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB **

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE **

Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
~~________~~
*Filed herewith.

43
~~Table of Contents~~
**XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registrati0n statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

(1)
Incorporated by reference from our Registration Statement on Form SB-2, filed with the Commission on January 31, 2008

(2)
Incorporated by reference from our Registration Statement on Form S-1, filed with the Commission on November 6, 2012

(3)
Incorporated by reference from our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on February 6, 2019

(4)
Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on May 14, 2019.

(5)
Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on September 10, 2019.

(6)
Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on November 19, 2019

(7)
Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on December 23, 2019

(8)
Incorporated by reference from our Annual Report on Form 10-K, filed with the Commission on April 17, 2020

(9)
Incorporated by reference from our Quarterly Report on Form 10-Q for the period ended ~~September~~June 30, 2020, filed with the Commission on May 26, 2020

(10)
Incorporated by reference from our Current Report on Form 8-K filed with the Commission on June 11, 2020

(11)
Incorporated by reference from our Annual Report on Form 10-K for the period ended December 31, 2020, filed with the Commission on ~~September~~June 30, 2021

(12)
Incorporated by reference from our Current Report on Form 8-K filed with the Commission on October 1, 2021
(13)
Incorporated by reference from Amendment No. 1 to our Registration Statement on Form S-1 filed with the Commission on December 1, 2021
(14)
Incorporated by reference from Amendment No. 3 to our Registration Statement on Form S-1 filed with the Commission on December 20, 2021.
(15)
Incorporated by reference from Amendment No. 4 to our Registration Statement on Form S-1 filed with the Commission on January 19, 2022.
(16)
Incorporated by reference from our Current Report on Form 8-K filed with the Commission on January 19, 2022.
(17)
Incorporated by reference from our Amendment No. 1 to our Registration Statement on Form S-1 filed with the Commission on March 17, 2022
(18)
Incorporated by reference from our Current Report on Form 8-K filed with the Commission on April 1, 2022
(19)
Incorporated by reference from our Current Report on Form 8-K filed with the Commission on May 19, 2022

4442
Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SOBR Safe, Inc.

Dated: ~~November 15, 2021~~May 23, 2022
~~By:~~
/s/ David Gandini

By:
David Gandini

Its:
Chief Executive Officer and Principal Executive Officer

4543

PART I – FINANCIAL INFORMATION		3

ITEM 1	Condensed Consolidated Financial Statements	4

ITEM 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29

ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	3837

ITEM 4	Controls and Procedures	3937

PART II – OTHER INFORMATION		38

ITEM 1	Legal Proceedings	4038

ITEM 1A	Risk Factors	4038

ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	4038

ITEM 3	Defaults Upon Senior Securities	4138

ITEM 4	Mine Safety Disclosures	4139

ITEM 5	Other Information	4139

ITEM 6	Exhibits	4240

	September 30, 2021			December 31, 2020
	(Unaudited)			(Audited)
ASSETS

Current assets
Cash	$	2,185,233		$	232,842
Prepaid expenses		24,899			115,230
Total current assets		2,210,132			348,072

SOBR Safe Intellectual Technology, net of accumulated amortization of $513,952 and $224,854 at September 30, 2021 and December 31, 2020, respectively		3,340,723			3,629,821

Other assets		15,826			8,680
Total Assets	$	5,566,681		$	3,986,573

LIABILITIES & STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable	$	706,142		$	101,308
Accrued expenses		306,071			313,032
Accrued interest payable		193,177			134,444
Related party payables		29,404			28,624
Common stock subscriptions payable		228,046			253,688
Derivative liability		980,000			0
Convertible debenture payable
* Includes unamortized debt discount related to detached warrants and convertible debenture of $2,608,900 and none at September 30, 2021 and December 31, 2020, respectively		439,881	*		0
Current portion notes payable - related parties		11,810			11,810
Current portion notes payable - non-related parties		104,183			79,183
Total current liabilities		2,998,714			922,089

Notes payable -related parties-less current portion
* Includes unamortized debt discount and beneficial conversion feature related to detached warrants and convertible notes of $771,576 and none at September 30, 2021 and December 31, 2020, respectively		228,424	*		0
Notes payable -non-related parties-less current portion
* Includes unamortized debt discount and beneficial conversion feature related to detached warrants and convertible notes of $774,850 and none at September 30, 2021 and December 31, 2020, respectively		230,150	*		25,000

Total Liabilities		3,457,288			947,089
Stockholders' Equity
Preferred stock, $0.00001 par value; 19,300,000 shares authorized, no shares issued or outstanding as of September 30, 2021 and December 31, 2020		0			0
Series A Convertible Preferred stock, $0.00001 par value; 3,000,000 shares authorized, no shares issued or outstanding as of September 30, 2021 and December 31, 2020		0			0
Series A-1 Convertible Preferred stock, $0.00001 par value; 2,700,000 shares authorized, no shares issued or outstanding as of September 30, 2021 and December 31, 2020		0			0
Common stock, $0.00001 par value; 100,000,000 shares authorized; 25,981,203 and 25,922,034 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively		260			260
Additional paid-in capital		56,330,450			52,693,974
Accumulated deficit		(54,167,685	)		(49,601,220	)
Total SOBR Safe, Inc. stockholders' equity		2,163,025			3,093,014
Noncontrolling interest		(53,632	)		(53,530	)

Total Stockholders' Equity		2,109,393			3,039,484

Total Liabilities and Stockholders' Equity	$	5,566,681		$	3,986,573

The accompanying notes are an integral part of the condensed consolidated financial statements.

	For The Three Months Ended						For The Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2021			2020			2021			2020

Revenues	$	0		$	0		$	0		$	0

Operating expenses:
General and administrative		316,329			191,589			875,378			400,127
Stock-based compensation expense		147,163			0			334,228			41,302
Management salaries and consulting fees		632,964			352,266			1,682,557			1,103,828
Research and development		566,655			152,123			1,052,650			309,403
Asset impairment adjustment		0			0			0			25,320,555
Total operating expenses		1,663,111			695,978			3,944,813			27,175,215

Loss from operations		(1,663,111	)		(695,978	)		(3,944,813	)		(27,175,215	)

Other income (expense):
Loss on extinguishment of debt, net		0			0			-			(269,144	)
Gain on fair value adjustment - derivatives		0			0			0			60,650
Interest expense		(227,475	)		(41,622	)		(399,381	)		(107,253	)
Amortization of interest - conversion features		(130,830	)		0			(222,373	)		(1,407,675	)
Total other expense, net		(358,305	)		(41,622	)		(621,754	)		(1,723,422	)

Loss before provision for income taxes		(2,021,416	)		(737,600	)		(4,566,567	)		(28,898,637	)

Provision for income taxes		0			0			0			0

Net loss		(2,021,416	)		(737,600	)		(4,566,567	)		(28,898,637	)
Net (income) loss attributable to noncontrolling interest		4			(98	)		102			(48	)

Net loss attributable to SOBR Safe, Inc.		(2,021,412	)		(737,698	)		(4,566,465	)		(28,898,685	)
Accrued dividends on convertible preferred stock		0			(161,880	)		0			(161,880	)
Net loss attributable to common stockholders	$	(2,021,412	)	$	(899,578	)	$	(4,566,465	)	$	(29,060,565	)

Basic and diluted loss per common share	$	(0.08	)	$	(0.04	)	$	(0.18	)	$	(2.23	)

Weighted average number of common shares outstanding		25,981,203			20,046,424			25,974,042			13,030,845

	March 31,			December 31,
	2022			2021
ASSETS	(Unaudited)			(Audited)

Current assets
Cash	$	107,448		$	882,268
Accounts receivable		500			0
Inventory		104,950			39,461
Prepaid expenses		29,286			12,553
Total current assets		242,184			934,282

SOBR Safe Intellectual Technology, net of accumulated amortization of $706,684 and $610,318 at March 31, 2022 and December 31, 2021, respectively		3,147,991			3,244,357

Other assets		30,576			30,576
Total Assets	$	3,420,751		$	4,209,215

LIABILITIES & STOCKHOLDERS' DEFICIT

Current liabilities
Accounts payable	$	367,036		$	270,150
Accrued expenses		1,395,696			463,900
Accrued interest payable		309,809			252,110
Related party payables		95,320			82,883
Derivative liability		1,380,000			1,040,000
Convertible debenture payable
* Includes unamortized debt discount related to warrants, beneficial conversion feature and embedded conversion feature of none and $1,291,882 at March 31, 2022 and December 31, 2021, respectively		3,048,781	*		1,756,899	*
Current portion notes payable - related parties
* Includes unamortized debt discount related to warrants and beneficial conversion features of $259,658 and none at March 31, 2022 and December 31, 2021, respectively		302,152	*		11,810	*
Current portion notes payable - non-related parties
* Includes unamortized debt discount related to warrants and beneficial conversion features of $258,175 and none at March 31, 2022 and December 31, 2021, respectively		348,508	*		104,183	*
Total current liabilities		7,247,302			3,981,935

Notes payable -related parties-less current portion
* Includes unamortized debt discount related to warrants and beneficial conversion features of $262,604 and $645,547 at March 31, 2022 and December 31, 2021, respectively		187,396	*		354,453	*
Notes payable -non-related parties-less current portion
* Includes unamortized debt discount related to warrants and beneficial conversion features of $261,396 and $648,580 at March 31, 2022 and December 31, 2021, respectively		193,604	*		356,420	*

Total Liabilities		7,628,302			4,692,808
Stockholders' Deficit
Non Series Preferred stock, $0.00001 par value; 16,300,000 and 19,300,000 shares authorized at March 31, 2022 and December 31, 2021, respectively, no shares issued or outstanding at March 31, 2022 and December 31, 2021		0			0
Series A Convertible Preferred stock, $0.00001 par value; 3,000,000 shares authorized, no shares issued or outstanding at March 31, 2022 and December 31, 2021		0			0
Series A-1 Convertible Preferred stock, $0.00001 par value; 2,700,000 shares authorized, no shares issued or outstanding as of March 31, 2022 and December 31, 2021		0			0
Series B Convertible Preferred stock, $0.000001 par value: 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at March 31, 2022 and none at December 31, 2021, respectively		30			0
Common stock, $0.00001 par value; 100,000,000 shares authorized; 7,803,139 and 8,778,555 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively		78			88
Additional paid-in capital		58,887,152			57,041,447
Accumulated deficit		(63,041,171	)		(57,471,492	)
Total SOBR Safe, Inc. stockholders' deficit		(4,153,911	)		(429,957	)
Noncontrolling interest		(53,640	)		(53,636	)

Total Stockholders' Deficit		(4,207,551	)		(483,593	)

Total Liabilities and Stockholders' Deficit	$	3,420,751		$	4,209,215

	Common Stock				Preferred Stock									Stockholders' Equity						Total
			Amount				Amount		Additional					(Deficit)						Stockholders'
	Shares		($0.00001 Par)		Shares		($0.00001 Par)		Paid-in Capital		Accumulated Deficit			SOBR Safe, Inc.			Noncontrolling Interest			Equity (Deficit)

Balances at January 1, 2020		6,452,993	$	65		-	$	0	$	15,971,392	$	(19,511,168	)	$	(3,539,711	)	$	(53,410	)	$	(3,593,121	)
Common stock issued for compensation		601		0		-		0		20,800		0			20,800			0			20,800
Common stock issued due to stock warrants exercise		454,097		4		-		0		65,724		0			65,728			0			65,728
Common stock issued to settle related party payables		214,883		2		-		0		493,072		0			493,074			0			493,074
Common stock issued to settle accounts payable and accrued expenses		38,323		0		-		0		92,385		0			92,385			0			92,385
Common stock issued to settle related party debt		648,739		6		-		0		826,958		0			826,964			0			826,964
Common stock issued to settle non-related party debt		70,448		1		-		0		166,525		0			166,526			0			166,526
Paid-in capital - fair value of stock options vested		-		0		-		0		39,450		0			39,450			0			39,450
Paid-in capital - gain on related party debt conversion		-		0		-		0		124,291		0			124,291			0			124,291
Paid-in capital - gain on related party payables conversion		-		0		-		0		221,557		0			221,557			0			221,557
Paid-in capital - loss on debt extinguishment		-		0		-		0		116,893		0			116,893			0			116,893
Paid-in capital - beneficial conversion feature		-		0		-		0		174		0			174			0			174
Net loss for the period		-		0		-		0		0		(450,023	)		(450,023	)		149			(449,874	)
Balances at March 31, 2020		7,880,084	$	78		-	$	0	$	18,139,221	$	(19,961,191	)	$	(1,821,892	)	$	(53,261	)	$	(1,875,153	)

Common stock issued to settle accounts payable and accrued expenses		121,072		2		-		0		173,290		0			173,292			0			173,292
Common stock issued to settle related party payables		45,268		1		-		0		86,739		0			86,740			0			86,740
Common stock issued for asset purchase		12,000,000		120		-		0		27,119,880		0			27,120,000			0			27,120,000
Paid-in capital - beneficial conversion feature		-		0		-		0		1,407,501		0			1,407,501			0			1,407,501
Paid-in capital - fair value of stock warrants granted		-		0		-		0		695,454		0			695,454			0			695,454
Paid-in capital - gain on related party payables conversion		-		0		-		0		50,741		0			50,741			0			50,741
Paid-in capital - loss on extinguishment of convertible notes		-		0		-		0		273,462		0			273,462			0			273,462
Paid-in capital - fair value of stock options vested		-		0		-		0		257,482		0			257,482			0			257,482
Net loss for the period		-		0		-		0		0		(27,710,964	)		(27,710,964	)		(199	)		(27,711,163	)
Balances at June 30, 2020		20,046,424	$	201		-	$	0	$	48,203,770	$	(47,672,155	)	$	531,816		$	(53,460	)	$	478,356

Paid-in capital - fair value of stock options vested		-		0		-		0		46,617		0			46,617			0			46,617
Dividends payable-Series A-1 convertible preferred stock		-		0		-		0		0		(161,880	)		(161,880	)		0			(161,880	)
Net loss for the period		-		0		-		0		0		(737,698	)		(737,698	)		98			(737,600	)
Balances at September 30, 2020		20,046,424	$	201		-	$	0	$	48,250,387	$	(48,571,733	)	$	(321,145	)	$	(53,362	)	$	(374,507	)

Balances at January 1, 2021		25,922,034	$	260		-	$	0	$	52,693,974	$	(49,601,220	)	$	3,093,014		$	(53,530	)	$	3,039,484
Common stock issued to settle dividends - Series A-1 Convertible Preferred stock		43,169		0		-		0		107,880		0			107,880			0			107,880
Paid-in capital - fair value of stock options and RSU vested		-		0		-		0		105,013		0			105,013			0			105,013
Paid-in capital - relative fair value of stock warrants granted		-		0		-		0		619,381		0			619,381			0			619,381
Paid-in capital - beneficial conversion feature		-		0		-		0		480,619		0			480,619			0			480,619
Net loss for the period		-		0		-		0		0		(1,002,340	)		(1,002,340	)		(94	)		(1,002,434	)
Balances at March 31, 2021		25,965,203	$	260		-	$	0		54,006,867	$	(50,603,560	)	$	3,403,567		$	(53,624	)	$	3,349,943

Common stock issued for facility lease		16,000		0		-		0		49,600		0			49,600			0			49,600
Paid-in capital - fair value of stock options and RSU vested		-		0		-		0		138,010		0			138,010			0			138,010
Paid-in capital - relative fair value of stock warrants granted		-		0		-		0		473,327		0			473,327			0			473,327
Paid-in capital - beneficial conversion feature		-		0		-		0		428,595		0			428,595			0			428,595
Net loss for the period		-		0		-		0		0		(1,542,713	)		(1,542,713	)		(4	)		(1,542,717	)
Balances at June 30, 2021		25,981,203	$	260		-	$	0		55,096,399	$	(52,146,273	)	$	2,950,386		$	(53,628	)	$	2,896,758

Paid-in capital - fair value of stock options and RSU vested		-		0		-		0		387,003		0			387,003			0			387,003
Paid-in capital - relative fair value of stock warrants granted		-		0		-		0		847,048		0			847,048			0			847,048
Net loss for the period		-		0		-		0		0		(2,021,412	)		(2,021,412	)	$	(4	)		(2,021,416	)
Balances at September 30, 2021		25,981,203	$	260		-	$	0		56,330,450	$	(54,167,685	)	$	2,163,025		$	(53,632	)	$	2,109,393

	For The Three Months Ended March 31,
	2022			2021
	(Unaudited)			(Unaudited)
Revenues	$	1,500		$	0
Cost of Goods Sold		1,100			0
Gross Profit		400			0

Operating expenses:
General and administrative		2,269,175			776,861
Stock-based compensation expense		442,784			18,690
Research and development		47,459			171,463
Total operating expenses		2,759,418			967,014

Loss from operations		(2,759,018	)		(967,014	)

Other income (expense):
Other income (expense), net		27			0
Loss on debt extinguishment		(864,000	)		0
Loss on fair value adjustment - derivatives		(340,000	)		0
Interest expense		(1,026,471	)		(25,878	)
Amortization of interest - beneficial conversion feature		(580,221	)		(9,542	)
Total other expense, net		(2,810,665	)		(35,420	)

Loss before provision for income taxes		(5,569,683	)		(1,002,434	)

Provision for income tax		0			0

Net loss		(5,569,683	)		(1,002,434	)
Net loss attributable to noncontrolling interest		4			94
Net loss attributable to SOBR Safe, Inc.	$	(5,569,679	)	$	(1,002,340	)

Basic and diluted loss per common share	$	(0.65	)	$	(0.12	)

Weighted average number of common shares outstanding		8,550,490			8,654,108

SOBR SAFE, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	For The Nine Months Ended
	September 30,
	2021			2020

Operating Activities:
Net loss	$	(4,566,567	)	$	(28,898,637	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		289,098			133,571
Loss on debt extinguishment, net		0			269,144
Change in fair value of derivative liability		0			(60,650	)
Amortization of interest - conversion features		222,373			1,407,675
Amortization of interest		275,052			8,656
Stock options expense		399,259			343,549
Stock-based compensation expense		334,228			41,302
Asset impairment adjustment		0			25,320,555
Changes in assets and liabilities:
Prepaid expenses		(19,361	)		994
Other assets		(7,146	)		(8,680	)
Accounts payable		604,834			140,906
Accrued expenses		(6,961	)		(83,495	)
Accrued interest payable		58,733			(6,697	)
Related party payables		780			(51,976	)
Common stock subscriptions payable		138,069			0

Net cash used in operating activities		(2,277,609	)		(1,443,783	)

Financing Activities:
Proceeds from notes payable - related parties		1,030,000			0
Repayments of notes payable - related parties		(30,000	)		0
Proceeds from notes payable - non-related parties		1,005,000			41,665
Proceeds from convertible debenture payable		2,500,000			0
Debt issuance costs		(275,000	)		0
Proceeds from offering of preferred stock - related parties		0			1,700,000
Net cash provided by financing activities		4,230,000			1,741,665

Net Change In Cash		1,952,391			297,882

Cash At The Beginning Of The Period		232,842			681,759

Cash At The End Of The Period	$	2,185,233		$	979,641

Schedule Of Non-Cash Investing And Financing Activities:

Issuance of common shares for rent	$	49,600		$	0

Issuance of common stock for prior year accrued dividends	$	107,880		$	0

Intrinsic value-beneficial conversion feature	$	909,214		$	1,407,501

Relative fair value of stock warrants granted	$	1,939,756		$	0

Convertible debenture payable discount	$	823,781		$	0

Fair value of embedded conversion feature	$	980,000		$	0

Gain on related party payables converted to capital	$	0		$	272,299

Accounts payable and accrued expenses converted to capital	$	0		$	265,677

Related party payables converted to capital	$	0		$	579,814

Related party debt converted to capital after exercise of cashless stock warrants	$	0		$	65,728

Related party debt converted to capital	$	0		$	826,964

Non-related party debt converted to capital	$	0		$	166,526

Gain on related party debt converted to capital	$	0		$	124,291

Shares issued for cash received in prior years	$	0		$	20,800

Issuance of common stock, stock warrants and convertible note for asset purchase	$	0		$	29,222,955

Preferred stock dividend accrued	$	0		$	161,880

Supplemental Disclosure:

Cash paid for interest	$	67,618		$	765

Cash paid for income taxes	$	0		$	0

The accompanying notes are an integral part of the condensed consolidated financial statements.

	1.	~~To remove and re-elect four (4) directors to serve until the next Annual Meeting of Shareholders and thereafter until their successors are elected and qualified; and~~

	2.	To approve an amendment to the Company’s Certificate of Incorporation to: (a) change the Company’s name to SOBR SAFE, Inc., (b) decrease the Company’s authorized common stock from 800,000,000 shares, par value $0.00001 to 100,000,000 shares, par value $0.00001, and (c) effect a reverse ~~stock~~ split of the Company’s outstanding common stock at a ratio between 1-for-32 and 1-for-35 (with the exact ratio to be determined by the directors in their sole discretion without further approval by the shareholders).

	Level 1		Level 2		Level 3
Derivative liability	$	0	$	0	$	980,000
	$	0	$	0	$	980,000

March 31, 2022	Level 1		Level 2		Level 3
Derivative liabilities	$	0	$	0	$	1,380,000

December 31, 2021	Level 1		Level 2		Level 3
Derivative liabilities	$	0	$	0	$	1,040,000

Property and equipment	$	47,725
Intangible assets		29,175,230
Total assets	$	29,222,955

Net purchase (fair value of stock issued, warrants and notes payable)	$	29,222,955

Intangible assets	$	29,175,230
Less: Asset impairment		25,320,555
Intangible assets, net of impairment	$	3,874,965

	September 30,		December 31,		March 31, 2022		December 31, 2021
	2021		2020
Consulting service	$	0	$	111,860
Rent		20,667		0
Insurance		4,232		3,370	$	4,286	$	4,286
Consulting services						25,000		8,267
Prepaid expenses	$	24,899	$	115,230	$	29,286	$	12,553

2022				2023				2024				2025				2026				Thereafter
$	385,467			$	385,467			$	385,467			$	385,467			$	385,467			$	1,413,388

	Gross Carrying		Accumulated		Net Intangible		Amortization Period
	Amount		Amortization		Asset		(in years)
SOBR Safe
Intellectual Technology	$	3,854,675	$	610,318	$	3,244,357		10

	March 31, 2022		December 31, 2021
Convertible debt default penalty (see Note 9)	$	914,634	$	0
Registration rights and default damages and penalties (see Note 9)		192,399		189,663
Consulting services		178,647		163,647
Taxes and other		110,016		110,590
Accrued expenses	$	1,395,696	$	463,900

Balance at December 31, 2021	$	1,040,000
Fair value of derivatives issued		0
Fair value adjustments		340,000
Balance at March 31, 2022	$	1,380,000

	September 30, 2021			September 30, 2020
Exercise Price	$	3.00-2.00		$	0.50
Dividend Yield		0	%		0	%
Volatility		158-120	%		153	%
Risk-free Interest Rate		0.14%-0.98	%		0.29	%
Life of Warrants		2-5 Years			5 Years

	March 31, 2022			March 31, 2021
Exercise Price	$	6.00		$	9.00
Dividend Yield		0	%		0	%
Volatility		110	%		158	%
Risk-free Interest Rate		2.45	%		0.14	%
Life of Warrants	7 Years			2 Years

	Warrants Outstanding Number of Shares			Exercise Price Per Share		Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value		Warrants Outstanding Number of Shares			Exercise Price Per Share		Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2019		598,414		$	0.13304–1.039375	3.97 Years	$	0.3607	$	1,276,870
Balance at December 31, 2020												194,772		$	1.50 – 6.00	3.80 Years	$	2.82	$	1,173,737
Warrants Granted		320,000		$	0.50	4.68Years	$	0.50	$	761,000		183,333		$	6.00	1.96 Years	$	9.00	$	66,000
Warrants Exercised		(454,097	)	$	0.13304 - 0.15299		$	0.1451				(58,979	)	$	1.50	0.50 Years	$	1.50
Warrants Expired		-										-
Balance at September 30, 2020		464,317		$	0.50- 1.039375	3.91 Years	$	0.66765	$	1,027,234
Balance at March 31, 2021												319,126		$	1.50 – 6.00	2.52 Years	$	6.62	$	875,493

	Warrants Outstanding Number of Shares		Exercise Price Per Share		Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2021		836,464	$	1.50 – 9.00	3.04 Years	$	6.78	$	1,784,838
Warrants Granted		101,626	$	6.00	7.00 Years	$	6.00	$	152,439
Warrants Exercised		-	$	0		$	0	$	-
Warrants Expired/Forfeited		-	$	-		$	0	$	-
Balance at March 31, 2022		938,090	$	1.50 – 9.00	4.14 Years	$	6.69	$	757,863

	Options Outstanding Number of Shares		Exercise Price Per Share		Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value		Options Outstanding Number of Shares			Exercise Price Per Share	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2019		2,381,239	$	0.2634-1.039	8.86 Years	$	0.2948	$	5,238,080
Balance at December 31, 2020											857,409	$	0.7902 – 9.90	7.45 Years	$	1.4997	$	6,302,277
Options Granted		160,000	$	0.26341-3.30	4.10 Years	$	1.9454	$	149,532		-
Options Exercised		-									-
Options Cancelled		-
Options Expired		-									-
Balance at September 30, 2020		2,541,239	$	0.2634 – 3.30	7.86 Years	$	0.3987	$	6,305,579
Balance at March 31, 2021											857,409	$	0.7902 – 9.90	7.21 Years	$	1.4497	$	6,739,385

Exercisable at December 31, 2020			1,253,030			$	0.2634 – 3.300			7.4 Years		$	0.3165			$	3,299,765
Exercisable at September 30, 2021			1,943,652			$	0.2634 – 3.575			6.3 Years		$	0.6527			$	3,590,430

	RSUs		Weighted Average Grant Date Fair Value Per Share		Weighted Average Vesting Period
Unvested at December 31, 2020		71,667	$	8.75	1.70 Years
Granted		-
Vested		-
Unvested at March 31, 2021		71,667	$	8.75	1.45 Years

	o	summarizes our plan of operation; and

	o	analyzes our financial condition and the results of our operations for the ~~three and nine months~~three-months ended ~~September 30, 2021.~~March 31, 2022.

	Three Months Ended September 30,						Three Months Ended March 31,
	2021			2020			2022			2021
Revenue	$	-		$	-		$	1,500		$	-
Cost of goods sold								1,100			-
Gross Profit								400			-

Operating expenses:

General and administrative		316,329			191,589			2,269,175			776,861
Stock-based compensation expense		147,163			-			442,784			18,690
Management salaries and consulting fees		632,964			352,266
Research and development		566,655			152,123			47,459			171,463
Asset impairment adjustment		-			-

Total operating expenses		1,663,111			695,978			2,759,418			967,014

Operating loss		(1,663,111	)		(695,978	)		(2,759,018	)		(916,014	)

Other income (expense):
Loss on extinguishment of debt, net		-			-
Gain on fair value adjustment – derivatives		-			-
Other income (expense), net								27			-
Loss on extinguishment of debt								(864,000	)		-
Loss on fair value adjustment – derivatives								(340,000	)		-
Interest expense		(227,475	)		(41,622	)		(1,026,471	)		(25,878	)
Amortization of interest – conversion features		(130,830	)		-			(580,221	)		(9,542	)
Total other expense, net		(358,305	)		(41,622	)		(2,810,665	)		(35,420	)

Net loss	$	(2,021,416	)	$	(737,600	)	$	(5,569,683	)	$	(1,002,434	)

	Nine Months Ended September 30,
	2021			2020
Revenue	$	-		$	-

Operating expenses:

General and administrative		875,378			400,127
Stock-based compensation expense		334,228			41,302
Management salaries and consulting fees		1,682,557			1,103,828
Research and development		1,052,650			309,403
Asset impairment adjustment		-			25,320,555
Total operating expenses		3,944,813			27,175,215

Operating loss		(3,944,813	)		(27,175,215	)

Other income (expense):
Loss on extinguishment of debt, net		-			(269,144	)
Gain on fair value adjustment – derivatives		-			60,650
Interest expense		(399,381	)		(107,253	)
Amortization of interest – conversion features		(222,373	)		(1,407,675	)
Total other expense, net		(621,754	)		(1,723,422	)

Net loss	$	(4,566,567	)	$	(28,898,637	)

	September 30, 2021		December 31, 2020		Change
							March 31, 2022		December 31, 2021		Change
Cash	$	2,185,233	$	232,842	$	1,952,391	$	107,448	$	882,268	$	(774,820	)
Total Current Assets	$	2,210,132	$	348,072	$	1,862,060		242,184		934,282		(692,098	)
Total Assets	$	5,566,681	$	3,986,573	$	1,580,108		3,420,751		4,209,215		(788,464	)
Total Current Liabilities	$	2,998,714	$	922,089	$	2,076,625		7,247,302		3,981,935		3,265,367
Total Liabilities	$	3,457,289	$	947,089	$	2,510,200		7,628,302		4,652,808		2,975,494

Item No.		Description
	~~Description~~
1.1 (19)		Underwriting Agreement by and between SOBR Safe, Inc. and Aegis Capital Corp. dated May, 2022

3.1 (1)		Articles of Incorporation of Imagine Media, Ltd.

3.2 (2)		Articles of Amendment to Articles of Incorporation to TransBiotec, Inc.

3.3 (3)		Certificate of Amendment to Certificate of Incorporation filed with the State of Delaware on May 25, 2017

3.4 (6)		Amended and Restated Bylaws of SOBR Safe, Inc.

3.5 (10)		Certificate of Amendment to Certificate of Incorporation of TransBiotec, Inc. changing name to SOBR Safe, Inc., effecting 1-for-33.26 reverse stock split and decreasing authorized common stock to 100M shares

4.1 (19)		Form of Representative’s Warrant

4.2 (19)		Warrant Agency Agreement

4.3 (19)		Form of Unit Warrant

10.1 (4)		Asset Purchase Agreement dated May 6, 2019 between IDTEC, LLC and TransBiotec, Inc.

10.2 (5)		Common Stock Purchase Agreement with Charles Bennington dated August 23, 2019

10.3 (5)		Share Exchange Agreement with Michael Lanphere dated August 23, 2019

10.4 (5)		Share Exchange Agreement with Vernon Justus dated August 23, 2019

10.5 (5)		Debt Conversion and Common Stock Purchase Agreement with Michael Lanphere dated August 23, 2019

10.6 (5)		Debt Conversion and Common Stock Purchase Agreement with Devadatt Mishal dated August 23, 2019

10.7 (6)		TransBiotec, Inc. 2019 Equity Incentive Plan

10.8 (6)		Employment Agreement with Kevin Moore dated October 25, 2019

10.9 (8)		Amended Employment Agreement with Kevin Moore dated November 26, 2019

10.10 (6)		Employment Agreement with David Gandini dated October 25, 2019

10.11 (7)		Series A-1 Preferred Stock Purchase Agreement by and between TransBiotec, Inc. and SOBR SAFE, LLC dated December 12, 2019 (with Series A-1 Preferred Stock Certificate of Designation attached)

10.12 (9)		Amendment No. 1 to Asset Purchase Agreement dated March 23, 2020 by and between IDTEC, LLC and TransBiotec, Inc.

10.13 (10)		Form of Convertible Promissory Note Issued to IDTEC, LLC at Close of Asset Purchase Transaction

10.14 (10)		Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement dated June 5, 2020 by and between IDTEC, LLC and TransBiotec, Inc.

10.15 (10)		Warrant to Purchase Common Stock dated June 5, 2020 issued to IDTEC, LLC

10.16 (11)		Advisory Agreement with Steven Beabout dated October 9, 2020

10.17 (12)		18% Original Issue Discount Convertible Debenture issued by SOBR Safe, Inc. to ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.18 (12)		Warrant to Purchase Common Stock issued by SOBR Safe, Inc. to ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.19 (12)		Securities Purchase Agreement by and between SOBR Safe, Inc. and ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.20 (12)		Registration Rights Agreement by and between SOBR Safe, Inc. and ~~a leading healthcare fund~~Armistice Capital Master Fund Ltd. dated September 27, 2021

10.21 (13)		“Form of” Secured Convertible Debenture issued by SOBR Safe, Inc. in $2M Regulation D Offering

10.22 (13)		“Form of” Warrant issued by SOBR Safe, Inc. in Regulation D Offering

10.23 (14)		Transition Agreement by and between SOBR Safe, Inc. and Kevin Moore dated October 30, 2021

10.24(15)		Executive Employment Agreement with Scott Bennett dated August 17, 2021

10.25(15)		Executive Employment Agreement with Michael Watson dated October 11, 2021

10.27 (16)		Executive Employment Agreement with Gerard Wenzel dated January 1, 2022

10.28 (17)		Form of Share Exchange Agreement with David Gandini and Gary Graham for Series B Preferred Stock

10.29 (18)		Waiver by and between SOBR Safe, Inc. and Armistice Capital Master Fund Ltd. dated March 30, 2022

31.1*		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer (filed herewith)

31.2*		Rule 13a-14(a)/15d-14(a) Certification of Chief Accounting Officer (filed herewith)

32.1*		Section 1350 Certification of Chief Executive Officer (filed herewith).